

Siegfried Kasper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1570572/publications.pdf>

Version: 2024-02-01

876
papers

36,822
citations

3874

91
h-index

10129

145
g-index

1004
all docs

1004
docs citations

1004
times ranked

26327
citing authors

#	ARTICLE	IF	CITATIONS
1	Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 65-74.	1.8	5
2	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 51-63.	1.8	4
3	Subthreshold depression – concept, operationalisation and epidemiological data. A scoping review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 92-106.	1.2	8
4	Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 59-68.	1.2	1
5	Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 277-286.	1.2	5
6	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2022, 27, 716-723.	0.7	3
7	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 115-126.	1.0	31
8	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022, 296, 485-492.	2.0	3
9	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2022, 55, 86-95.	0.3	19
10	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	2.5	3
11	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. <i>International Clinical Psychopharmacology</i> , 2022, 37, 38-45.	0.9	9
12	Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 715-718.	1.3	6
13	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	1.8	14
14	Incidence of Drug-Induced Delirium During Treatment With Antidepressants or Antipsychotics: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2016. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 556-566.	1.0	6
15	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. <i>European Neuropsychopharmacology</i> , 2022, 56, 100-111.	0.3	5
16	Polygenic risk scores for neuropsychiatric, inflammatory, and cardiovascular metabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2022, 189, 74-85.	1.1	8
17	Editorial 1. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 1-2.	1.2	0
18	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytochemicals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	1.3	49

#	ARTICLE	IF	CITATIONS
19	Initiating Antidepressant Medication: What is the Most Important Factor?. <i>Advances in Therapy</i> , 2022, , 1.	1.3	0
20	Sick leave duration as a potential marker of functionality and disease severity in depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 406-416.	1.2	5
21	Is treatment-resistant depression really resistant?. <i>European Neuropsychopharmacology</i> , 2022, 58, 44-46.	0.3	4
22	BDNF gene polymorphisms predicting treatment response to CBT-based rehabilitation of depression. <i>European Neuropsychopharmacology</i> , 2022, 58, 103-108.	0.3	4
23	Cariprazine for treating psychosis: an updated meta-analysis. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, , 1-3.	1.2	0
24	Oxytocin receptor gene methylation as a molecular marker for severity of depressive symptoms in affective disorder patients. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	3
25	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. <i>Journal of Affective Disorders</i> , 2022, 312, 225-234.	2.0	2
26	Regional gene expression patterns are associated with task-specific brain activation during reward and emotion processing measured with functional MRI. <i>Human Brain Mapping</i> , 2022, 43, 5266-5280.	1.9	2
27	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 483-494.	1.3	32
28	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-15.	1.3	38
29	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , 2021, 26, 562-586.	0.7	13
30	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	0.7	5
31	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110050.	2.5	21
32	Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. <i>Journal of Psychiatric Research</i> , 2021, 136, 543-551.	1.5	4
33	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021, 279, 722-729.	2.0	7
34	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110170.	2.5	36
35	Reconceptualising treatment-resistant depression as difficult-to-treat depression. <i>Lancet Psychiatry</i> , 2021, 8, 14-15.	3.7	19
36	No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 171-180.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Combining machine learning algorithms for prediction of antidepressant treatment response. <i>Acta Psychiatrica Scandinavica</i> , 2021, 143, 36-49.	2.2	31
38	Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 22-31.	1.0	280
39	Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET. <i>Molecular Psychiatry</i> , 2021, 26, 1009-1018.	4.1	23
40	Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia. <i>NeuroImage: Clinical</i> , 2021, 32, 102813.	1.4	5
41	Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 849-862.	0.9	19
42	Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis. <i>Brain and Behavior</i> , 2021, 11, e01997.	1.0	11
43	Case Report: Bupropion Reduces the [123I]FP-CIT Binding to Striatal Dopamine Transporter. <i>Frontiers in Psychiatry</i> , 2021, 12, 631357.	1.3	2
44	The Influence of Acute SSRI Administration on White Matter Microstructure in Patients Suffering From Major Depressive Disorder and Healthy Controls. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 542-550.	1.0	15
45	Editorial 1. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 1-1.	1.2	7
46	Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial. <i>Translational Psychiatry</i> , 2021, 11, 200.	2.4	15
47	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	2.0	4
48	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	4.0	270
49	Editorial 2. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 107-108.	1.2	0
50	Reliability of task-specific neuronal activation assessed with functional PET, ASL and BOLD imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2986-2999.	2.4	18
51	Wirksamkeit von Silexan bei generalisierter Angststörung: Re-Analyse einer randomisierten klinischen Prüfung mit modernen statistischen Methoden. , 2021, 42, .		0
52	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021, 38, 896-906.	2.0	18
53	How to prevent and manage hyperammonemic encephalopathies in valproate therapy. <i>Journal of Affective Disorders Reports</i> , 2021, 5, 100186.	0.9	3
54	Meta-analysis of brain structural changes after electroconvulsive therapy in depression. <i>Brain Stimulation</i> , 2021, 14, 927-937.	0.7	25

#	ARTICLE	IF	CITATIONS
55	Melancholic features in major depression – a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110285.	2.5	17
56	Monoamino Oxidase A Gene Single-Nucleotide Polymorphisms and Methylation Status and the Risk of Violent Suicide Attempts in Affective Disorder Patients. <i>Frontiers in Psychiatry</i> , 2021, 12, 667191.	1.3	2
57	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021, 28, 4296-4320.	1.2	1
58	Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 1-10.	1.2	3
59	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021, 141, 167-175.	1.5	14
60	Obituary – Prof. Dr. Hanns Hippus (1925 – 2021). <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 856-857.	1.0	1
61	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	1.0	2
62	Urological adverse drug reactions of psychotropic medication in psychiatric inpatients – A drug surveillance report from German-speaking countries. <i>Journal of Psychiatric Research</i> , 2021, 144, 412-420.	1.5	4
63	Neuroimaging in Seasons and Winter Depression. , 2021, , 245-259.		0
64	Editorial 4. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 331-332.	1.2	0
65	Letter to BJPsych in response to Horowitz and Moncrieff. <i>British Journal of Psychiatry</i> , 2021, 219, 619-620.	1.7	1
66	Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 67-75.	1.0	19
67	The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 17-24.	4.0	65
68	Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm. <i>NeuroImage</i> , 2020, 204, 116244.	2.1	33
69	Brain glucose uptake during transcranial direct current stimulation measured with functional [18F]FDG-PET. <i>Brain Imaging and Behavior</i> , 2020, 14, 477-484.	1.1	5
70	Sex Matters: A Multivariate Pattern Analysis of Sex- and Gender-Related Neuroanatomical Differences in Cis- and Transgender Individuals Using Structural Magnetic Resonance Imaging. <i>Cerebral Cortex</i> , 2020, 30, 1345-1356.	1.6	23
71	Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance programme. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 308-316.	1.3	14
72	Life-long epigenetic programming of cortical architecture by maternal –Western– diet during pregnancy. <i>Molecular Psychiatry</i> , 2020, 25, 22-36.	4.1	28

#	ARTICLE	IF	CITATIONS
73	Changes in White Matter Microstructure After Electroconvulsive Therapy for Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 20-25.	1.0	16
74	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109835.	2.5	32
75	The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 230-256.	1.0	38
76	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.3	14
77	Torgny Svensson, a superb mind and an inspiring colleague. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 543-544.	1.0	0
78	Oral Ketamine as a Treatment Option in Patients With Treatment Resistant Depression and Comorbid Arterial Hypertension. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 418-420.	0.7	1
79	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 329-329.	1.2	0
80	Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge. <i>Frontiers in Computational Neuroscience</i> , 2020, 14, 554186.	1.2	11
81	Editorial 3. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 217-218.	1.2	0
82	Prognosis and Improved Outcomes in Major Depression: A Review. <i>Focus (American Psychiatric)</i> 10 Tf 50 30 0,4 21	0,4	21
83	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 571-577.	1.0	5
84	Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain. <i>NeuroImage</i> , 2020, 223, 117270.	2.1	11
85	Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 440-445.	1.0	23
86	Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data. <i>Cerebral Cortex</i> , 2020, 30, 3771-3780.	1.6	10
87	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020, 10, 50.	2.4	33
88	The identification, assessment and management of difficult-to-treat depression: An international consensus statement. <i>Journal of Affective Disorders</i> , 2020, 267, 264-282.	2.0	133
89	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. <i>Translational Psychiatry</i> , 2020, 10, 2.	2.4	25
90	Molecular neuroimaging of the serotonergic system with Positron Emission Tomography. <i>Handbook of Behavioral Neuroscience</i> , 2020, 31, 175-194.	0.7	2

#	ARTICLE	IF	CITATIONS
91	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 720, 134754.	1.0	9
92	Management of mild cognitive impairment (MCI): The need for national and international guidelines. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 579-594.	1.3	100
93	Machine learning classification of ADHD and HC by multimodal serotonergic data. <i>Translational Psychiatry</i> , 2020, 10, 104.	2.4	39
94	A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2020, 35, 137-146.	0.9	26
95	Adverse effects of δ^9 -tetrahydrocannabinol on neuronal bioenergetics during postnatal development. <i>JCI Insight</i> , 2020, 5, .	2.3	12
96	Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	145
97	Reconfiguration of functional brain networks and metabolic cost converge during task performance. <i>ELife</i> , 2020, 9, .	2.8	49
98	Dose-response relationship of selective serotonin reuptake inhibitors. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 427-429.	2.2	0
99	Personalised and precision psychiatry: what do the CINP bipolar guidelines suggest?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 80-81.	1.2	2
100	Usage of Therapeutic Sleep Deprivation: A Survey in Psychiatric Hospitals in Austria, Germany, and Switzerland. <i>Behavioral Sleep Medicine</i> , 2019, 17, 713-720.	1.1	6
101	Results of the European Group for the Study of Resistant Depression (GSRD) as a basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 427-448.	1.3	89
102	Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks. <i>Scientific Reports</i> , 2019, 9, 11484.	1.6	13
103	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 83-83.	1.2	0
104	Repetitive enhancement of serum BDNF subsequent to continuation of ECT. <i>Acta Psychiatrica Scandinavica</i> , 2019, 140, 426-434.	2.2	19
105	Changes over time of the diagnostic and therapeutic characteristics of patients of a psychiatric intensive care unit in Austria. <i>Comprehensive Psychiatry</i> , 2019, 93, 20-26.	1.5	4
106	Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 172.	1.4	6
107	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. <i>European Neuropsychopharmacology</i> , 2019, 29, 971-985.	0.3	93
108	Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 560-573.	1.0	32

#	ARTICLE	IF	CITATIONS
109	Alcohol consumption in Austrian physicians. <i>Annals of General Psychiatry</i> , 2019, 18, 22.	1.2	9
110	Manifesto for an international digital mental health network. <i>Digital Psychiatry</i> , 2019, 2, 14-24.	2.1	14
111	A thank-you note from the Chief-Editor. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 254-257.	1.3	0
112	Predicting Ventral Striatal Activation During Reward Anticipation From Functional Connectivity at Rest. <i>Frontiers in Human Neuroscience</i> , 2019, 13, 289.	1.0	5
113	Editorial issue 3/2019. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 163-163.	1.2	0
114	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	1.0	28
115	High occupational level is associated with poor response to the treatment of depression: A replication study. <i>European Neuropsychopharmacology</i> , 2019, 29, 349-355.	0.3	3
116	Seasonality of antidepressant prescriptions and sick leaves. <i>Journal of Psychiatric Research</i> , 2019, 111, 128-133.	1.5	9
117	Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. <i>Translational Psychiatry</i> , 2019, 9, 5.	2.4	7
118	Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseases. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 134-148.	1.2	5
119	Hippocampal Subfields in Acute and Remitted Depression – an Ultra-High Field Magnetic Resonance Imaging Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 513-522.	1.0	22
120	Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. <i>European Neuropsychopharmacology</i> , 2019, 29, 711-719.	0.3	11
121	Characterization of pharmacological response to selective serotonin reuptake inhibitors using clustering of resting-state hybrid PET/MR data. <i>European Neuropsychopharmacology</i> , 2019, 29, S603-S604.	0.3	0
122	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109638.	2.5	20
123	Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019, 29, 777-785.	0.3	18
124	A case-control study of paternal and maternal age as risk factors in mood disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 90-98.	1.2	8
125	Acute and subsequent continuation electroconvulsive therapy elevates serum BDNF levels in patients with major depression. <i>Brain Stimulation</i> , 2019, 12, 1041-1050.	0.7	30
126	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 1-1.	1.2	0

#	ARTICLE	IF	CITATIONS
127	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , 2019, 252, 464-474.	2.0	27
128	On the suitability of medical analogies, from hypertension to broken leg. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 171-172.	1.3	3
129	Prognosis and improved outcomes in major depression: a review. <i>Translational Psychiatry</i> , 2019, 9, 127.	2.4	262
130	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. <i>Translational Psychiatry</i> , 2019, 9, 64.	2.4	43
131	Big Data Guided Interventions: Predicting Treatment Response. , 2019, , 53-76.		3
132	Editorial for Treatment-Resistant Depression (TRD). <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 83-84.	1.0	8
133	Editorial issue 4/2019. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 237-237.	1.2	1
134	Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. <i>Frontiers in Physiology</i> , 2019, 10, 1422.	1.3	5
135	Attrition in treatment-resistant depression. <i>International Clinical Psychopharmacology</i> , 2019, 34, 161-169.	0.9	0
136	Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study. <i>Pharmacopsychiatry</i> , 2019, 52, 193-202.	1.7	5
137	Circuit Mechanisms of Reward, Anhedonia, and Depression. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 105-118.	1.0	135
138	Making Sense of Connectivity. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 194-207.	1.0	22
139	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 2-16.	1.3	26
140	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. <i>European Psychiatry</i> , 2019, 56, 14-34.	0.1	330
141	Definition of treatment-resistant depression – Asia Pacific perspectives. <i>Journal of Affective Disorders</i> , 2019, 245, 626-636.	2.0	37
142	Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis. <i>British Journal of Psychiatry</i> , 2019, 214, 159-167.	1.7	71
143	Cutaneous adverse drug reactions to psychotropic drugs and their risk factors – a case-control study. <i>European Neuropsychopharmacology</i> , 2019, 29, 111-121.	0.3	15
144	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019, 214, 36-41.	1.7	44

#	ARTICLE	IF	CITATIONS
145	The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. <i>Brain Stimulation</i> , 2019, 12, 714-723.	0.7	24
146	Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. <i>Cerebral Cortex</i> , 2019, 29, 372-382.	1.6	12
147	Opinion paper: poor response to treatment of depression in people in high occupational levels. <i>Psychological Medicine</i> , 2019, 49, 49-54.	2.7	8
148	Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. <i>British Journal of Psychiatry</i> , 2019, 214, 27-35.	1.7	54
149	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 78-88.	2.2	92
150	Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 183-193.	1.8	37
151	The pulvinar nucleus and antidepressant treatment: dynamic modeling of antidepressant response and remission with ultra-high field functional MRI. <i>Molecular Psychiatry</i> , 2019, 24, 746-756.	4.1	23
152	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 93-104.	1.0	32
153	Therapeutic efficacy of the Ginkgo special extract EGb761 [®] within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 173-189.	1.3	45
154	Psychotic Features in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	28
155	Effects of lavender oil on insomnia in patients with anxiety disorders – a meta-analysis. <i>Planta Medica</i> , 2019, 85, .	0.7	0
156	Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. <i>Brain Structure and Function</i> , 2018, 223, 1369-1378.	1.2	34
157	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 539-549.	1.0	54
158	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 1-1.	1.2	0
159	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 401-412.	2.2	37
160	Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms. <i>Molecular Neurobiology</i> , 2018, 55, 7271-7284.	1.9	20
161	Stress management and the role of <i>Rhodiola rosea</i> : a review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 242-252.	1.2	39
162	Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 145-153.	1.0	22

#	ARTICLE	IF	CITATIONS
163	The Impact of COMT and Childhood Maltreatment on Suicidal Behaviour in Affective Disorders. <i>Scientific Reports</i> , 2018, 8, 692.	1.6	12
164	Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. <i>NeuroImage</i> , 2018, 171, 1-5.	2.1	6
165	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018, 28, 752-760.	0.3	47
166	DiGeorge syndrome. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 283-287.	1.0	16
167	Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. <i>NeuroImage</i> , 2018, 176, 259-267.	2.1	87
168	Venous thromboembolism during treatment with antipsychotics: Results of a drug surveillance programme. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 175-186.	1.3	23
169	Silexan in anxiety disorders: Clinical data and pharmacological background. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 412-420.	1.3	96
170	Paternal and maternal age as risk factors for schizophrenia: a case-control study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 170-176.	1.2	24
171	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study. <i>Journal of Affective Disorders</i> , 2018, 227, 254-259.	2.0	6
172	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 203-210.	2.5	31
173	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 330-348.	1.3	32
174	Effects of testosterone treatment on hypothalamic neuroplasticity in female-to-male transgender individuals. <i>Brain Structure and Function</i> , 2018, 223, 321-328.	1.2	24
175	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 2-58.	1.3	128
176	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018, 227, 777-786.	2.0	32
177	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2018, 22, 241-241.	1.2	0
178	Implementing prevention of seasonal affective disorder from patients' and physicians' perspectives - a qualitative study. <i>BMC Psychiatry</i> , 2018, 18, 372.	1.1	10
179	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: <i>HTTLPR</i> and other variants. <i>Human Psychopharmacology</i> , 2018, 33, e2682.	0.7	7
180	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018, 28, 1305-1313.	0.3	15

#	ARTICLE	IF	CITATIONS
181	Prediction of Autopsy Verified Neuropathological Change of Alzheimer's Disease Using Machine Learning and MRI. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 406.	1.7	26
182	Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. <i>Translational Psychiatry</i> , 2018, 8, 198.	2.4	22
183	Evidence for the Efficacy of Bright Light Therapy for Bipolar Depression. <i>American Journal of Psychiatry</i> , 2018, 175, 905-906.	4.0	11
184	Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 814-821.	1.0	34
185	Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI. <i>NeuroImage</i> , 2018, 181, 323-330.	2.1	59
186	Influence of CRHR1 Polymorphisms and Childhood Abuse on Suicide Attempts in Affective Disorders: A GxE Approach. <i>Frontiers in Psychiatry</i> , 2018, 9, 165.	1.3	9
187	Striatal dopaminergic alterations in Tourette's syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies. <i>Translational Psychiatry</i> , 2018, 8, 143.	2.4	29
188	Diversity matters: combinatorial information coding by GABAA receptor subunits during spatial learning and its allosteric modulation. <i>Cellular Signalling</i> , 2018, 50, 142-159.	1.7	5
189	Rapid antidepressant effect of S-ketamine in schizophrenia. <i>European Neuropsychopharmacology</i> , 2018, 28, 980-982.	0.3	7
190	International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. <i>Pharmacological Reviews</i> , 2018, 70, 475-504.	7.1	42
191	Refining Prediction in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16m11385.	1.1	76
192	The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelines.. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, pyw109.	1.0	151
193	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, pyw072.	1.0	44
194	A proposal for a psychopharmacology's pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 29-38.	1.3	13
195	Administration of ketamine for unipolar and bipolar depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 2-12.	1.2	84
196	Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 113-119.	2.5	3
197	Default mode network deactivation during emotion processing predicts early antidepressant response. <i>Translational Psychiatry</i> , 2017, 7, e1008-e1008.	2.4	63
198	Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. <i>NeuroImage</i> , 2017, 149, 23-32.	2.1	19

#	ARTICLE	IF	CITATIONS
199	Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia. <i>International Psychogeriatrics</i> , 2017, 29, 1223-1225.	0.6	4
200	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , 2017, 91, 1-13.	1.5	77
201	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 723-735.	1.8	21
202	Effects of sex hormone treatment on white matter microstructure in individuals with gender dysphoria. <i>NeuroImage</i> , 2017, 150, 60-67.	2.1	30
203	A new nomenclature for classifying psychotropic drugs. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1614-1616.	1.1	26
204	Silexan does not cause withdrawal symptoms even when abruptly discontinued. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 177-180.	1.2	11
205	Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain. <i>Cerebral Cortex</i> , 2017, 27, 117-130.	1.6	30
206	Pregabalin for generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 49-55.	0.9	52
207	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , 2017, 27, 625-632.	0.3	19
208	The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. <i>Translational Psychiatry</i> , 2017, 7, e1150-e1150.	2.4	22
209	Norepinephrine transporter gene and protein expression of the human brain investigated with postmortem data and PET. <i>European Neuropsychopharmacology</i> , 2017, 27, S73-S74.	0.3	0
210	Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 77, 317-326.	2.9	296
211	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 86-119.	1.3	55
212	Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control. <i>NeuroImage</i> , 2017, 147, 198-203.	2.1	22
213	Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2017, 86, 283-291.	4.0	32
214	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 782-787.	1.0	10
215	Systematic evaluation of dose-escalation strategies after initial non-response to standard-dose pharmacotherapy in schizophrenia. <i>European Psychiatry</i> , 2017, 41, S193-S193.	0.1	0
216	Alternating intravenous racemic ketamine and electroconvulsive therapy in treatment resistant depression: A case report. <i>European Psychiatry</i> , 2017, 41, S522-S522.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression. <i>Journal of ECT</i> , 2017, 33, e31-e32.	0.3	5
218	Case Report. <i>Journal of ECT</i> , 2017, 33, e2-e3.	0.3	1
219	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 1-1.	1.2	2
220	Ketamine for the Treatment of Depression. <i>JAMA Psychiatry</i> , 2017, 74, 970.	6.0	8
221	Evidence-based pharmacotherapy of treatment-resistant unipolar depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 13-23.	1.2	90
222	Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. <i>Human Brain Mapping</i> , 2017, 38, 792-802.	1.9	21
223	Ketamine-dependent neuronal activation in healthy volunteers. <i>Brain Structure and Function</i> , 2017, 222, 1533-1542.	1.2	36
224	Has the existence of seasonal affective disorder been disproven?. <i>Journal of Affective Disorders</i> , 2017, 208, 54-55.	2.0	13
225	Making Sense of: Sensitization in Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 1-10.	1.0	44
226	Prevention of seasonal affective disorder: results of a survey in German-speaking countries. <i>European Journal of Public Health</i> , 2017, 27, .	0.1	0
227	Monoamine oxidase A distribution volume as a correlate for electroconvulsive therapy “ preliminary results. <i>European Neuropsychopharmacology</i> , 2017, 27, S708-S709.	0.3	1
228	Influence of serotonergic gene variants on serotonin transporter binding in ADHD. <i>European Neuropsychopharmacology</i> , 2017, 27, S707.	0.3	0
229	Reduced gray matter in subcortical brain regions in MDD: preliminary results of an ultra-high field 7 Tesla MRI Study. <i>European Neuropsychopharmacology</i> , 2017, 27, S719-S720.	0.3	0
230	Investigating dose dependency of ketamine binding on the serotonin transporter with positron emission tomography. <i>European Neuropsychopharmacology</i> , 2017, 27, S779.	0.3	0
231	Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 48.	1.0	50
232	Multicenter, open-label, exploratory clinical trial with <i>Rhodiola rosea</i> extract in patients suffering from burnout symptoms. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 889-898.	1.0	16
233	Prevention of seasonal affective disorder in daily clinical practice: results of a survey in German-speaking countries. <i>BMC Psychiatry</i> , 2017, 17, 247.	1.1	10
234	Silexan in generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 195-204.	0.9	19

#	ARTICLE	IF	CITATIONS
235	A New Prediction Model for Evaluating Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2017, 78, 215-222.	1.1	73
236	Elektrokonvulsionstherapie, Hirnstimulationsverfahren. , 2017, , 1-46.		0
237	Lichttherapie. , 2017, , 895-901.		0
238	Schlafentzugsbehandlung. , 2017, , 889-894.		0
239	Psychopharmakotherapie â€“ klinisch-empirische Grundlagen. , 2017, , 795-842.		1
240	Elektrokonvulsionstherapie, Hirnstimulationsverfahren. , 2017, , 843-887.		0
241	PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia. International Journal of Neuropsychopharmacology, 2016, 19, 74-74.	1.0	1
242	PS168. Hybrid PET/MR imaging of serotonin transporter occupancy and brain activation to elucidate the mechanism of action of selective serotonin reuptake inhibitors. International Journal of Neuropsychopharmacology, 2016, 19, 60-61.	1.0	0
243	Quantification of Task-Specific Glucose Metabolism with Constant Infusion of ¹⁸ F-FDG. Journal of Nuclear Medicine, 2016, 57, 1933-1940.	2.8	64
244	Psychiatric patients' perception of physical restraint. Acta Psychiatrica Scandinavica, 2016, 133, 221-231.	2.2	32
245	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment â€“ a European multicentre study. International Clinical Psychopharmacology, 2016, 31, 1-7.	0.9	19
246	Pregabalin in Touretteâ€™s Syndrome: A Case Series. American Journal of Psychiatry, 2016, 173, 1242-1243.	4.0	2
247	Estradiol level changes correlate with changes in mean diffusivity and fractional anisotropy values in female-to-male transsexuals. European Neuropsychopharmacology, 2016, 26, S202.	0.3	0
248	Attenuation of habenulaâ€™ default mode network connectivity by selective serotonin reuptake inhibitors, a pharmacological hybrid PET/MR study. European Neuropsychopharmacology, 2016, 26, S317.	0.3	1
249	Efficacy of Silexan in mixed anxietyâ€™depression â€“ A randomized, placebo-controlled trial. European Neuropsychopharmacology, 2016, 26, 331-340.	0.3	54
250	Gender transition affects neural correlates of empathy: A resting state functional connectivity study with ultra high-field 7T MR imaging. NeuroImage, 2016, 138, 257-265.	2.1	21
251	P.1.015 Surface-based clustering of serotonergic and adrenergic receptor mRNA expression in the human cortex. European Neuropsychopharmacology, 2016, 26, S15.	0.3	0
252	The relevance of â€™mixed anxiety and depressionâ€™ as a diagnostic category in clinical practice. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 725-736.	1.8	82

#	ARTICLE	IF	CITATIONS
253	Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration. <i>Psychoneuroendocrinology</i> , 2016, 74, 371-379.	1.3	46
254	High occupational level is associated with poor response to treatment of depression. <i>European Neuropsychopharmacology</i> , 2016, 26, 1320-1326.	0.3	8
255	Neuroscience-based Nomenclature (NbN): A call for action. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 318-320.	1.3	16
256	Testosterone affects language areas of the adult human brain. <i>Human Brain Mapping</i> , 2016, 37, 1738-1748.	1.9	47
257	Bipolar and related disorders in DSM-5 and ICD-10. <i>CNS Spectrums</i> , 2016, 21, 318-323.	0.7	25
258	The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. <i>International Journal of Neuropsychopharmacology</i> , 2016, 20, pyw100.	1.0	77
259	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1960-1971.	0.3	50
260	The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 1: Background and Methods of the Development of Guidelines. <i>International Journal of Neuropsychopharmacology</i> , 2016, 20, pyw091.	1.0	28
261	International Journal of Psychiatry in Clinical Practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 209-209.	1.2	0
262	Use of Light Therapy by Office-Based Physicians. <i>Neuropsychobiology</i> , 2016, 74, 182-187.	0.9	7
263	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 406-428.	1.3	30
264	Bipolar II disorder as a risk factor for postpartum depression. <i>Journal of Affective Disorders</i> , 2016, 204, 54-58.	2.0	30
265	Intramuscular maintenance treatment with ultra-high-dose long-acting injectable aripiprazole in an elderly patient suffering from chronic refractory schizophrenia: A case report. <i>European Psychiatry</i> , 2016, 33, S573-S573.	0.1	2
266	A European psychopharmacology curriculum: The young psychiatrist's point of view. <i>European Psychiatry</i> , 2016, 33, S63-S63.	0.1	0
267	Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults. <i>Brain Structure and Function</i> , 2016, 221, 103-114.	1.2	31
268	Effects of norepinephrine transporter gene variants on <sc>NET</sc> binding in <sc>ADHD</sc> and healthy controls investigated by <sc>PET</sc>. <i>Human Brain Mapping</i> , 2016, 37, 884-895.	1.9	37
269	Epidemiology and socioeconomic impact of seasonal affective disorder in Austria. <i>European Psychiatry</i> , 2016, 32, 28-33.	0.1	29
270	Meta-analysis of the COMT Val158Met polymorphism in major depressive disorder: the role of gender. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 147-158.	1.3	21

#	ARTICLE	IF	CITATIONS
271	Assessment and management of agitation in psychiatry: Expert consensus. World Journal of Biological Psychiatry, 2016, 17, 86-128.	1.3	204
272	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. World Journal of Biological Psychiatry, 2016, 17, 210-220.	1.3	4
273	Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program. International Journal of Neuropsychopharmacology, 2016, 19, pyv126.	1.0	41
274	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. Journal of Affective Disorders, 2016, 189, 224-232.	2.0	73
275	Hirnstimulationsverfahren, Elektrokonvulsionstherapie. , 2016, , 1-23.		0
276	Lichttherapie. , 2016, , 1-8.		0
277	Schlafentzugsbehandlung. , 2016, , 1-7.		0
278	P.1.i.047 Interregional changes in serotonin transporter availability upon treatment with selective serotonin reuptake inhibitors. European Neuropsychopharmacology, 2015, 25, S327-S328.	0.3	0
279	P.1.i.034 Gene expression and protein distribution of serotonergic key proteins in the human brain revealed by PET in vivo and postmortem quantification. European Neuropsychopharmacology, 2015, 25, S319-S320.	0.3	0
280	Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry, 2015, 14, 304-306.	4.8	14
281	Editorial. International Journal of Psychiatry in Clinical Practice, 2015, 19, 227-227.	1.2	0
282	Influence of Sex on Suicidal Phenotypes in Affective Disorder Patients with Traumatic Childhood Experiences. PLoS ONE, 2015, 10, e0137763.	1.1	24
283	Dose escalation of antipsychotic drugs in schizophrenia: A meta-analysis of randomized controlled trials. Schizophrenia Research, 2015, 166, 187-193.	1.1	24
284	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. Journal of Affective Disorders, 2015, 184, 51-59.	2.0	38
285	Reduced default mode network suppression during a working memory task in remitted major depression. Journal of Psychiatric Research, 2015, 64, 9-18.	1.5	99
286	Increasing placebo response in antipsychotic trials: a clinical perspective. Evidence-Based Mental Health, 2015, 18, 77-79.	2.2	10
287	Individual Diversity of Functional Brain Network Economy. Brain Connectivity, 2015, 5, 156-165.	0.8	16
288	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. International Journal of Psychiatry in Clinical Practice, 2015, 19, 158-167.	1.2	24

#	ARTICLE	IF	CITATIONS
289	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 441-453.	0.3	77
290	(S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling. <i>NeuroImage</i> , 2015, 108, 243-250.	2.1	39
291	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 472-482.	1.3	15
292	Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. <i>Psychotherapy and Psychosomatics</i> , 2015, 84, 110-116.	4.0	74
293	High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. <i>Biological Psychiatry</i> , 2015, 78, 525-533.	0.7	75
294	Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 199-208.	1.8	4
295	The serotonin transporter in psychiatric disorders: insights from PET imaging. <i>Lancet Psychiatry</i> , the, 2015, 2, 743-755.	3.7	140
296	Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. <i>NeuroImage</i> , 2015, 111, 505-512.	2.1	12
297	Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 217-228.	0.5	25
298	Structural Connectivity Networks of Transgender People. <i>Cerebral Cortex</i> , 2015, 25, 3527-3534.	1.6	66
299	Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv040.	1.0	93
300	Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , 2015, 15, 538-548.	0.9	34
301	Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. <i>European Neuropsychopharmacology</i> , 2015, 25, 763-772.	0.3	68
302	Voxel-based morphometry at ultra-high fields. A comparison of 7T and 3T MRI data. <i>NeuroImage</i> , 2015, 113, 207-216.	2.1	43
303	Treatment of depressive symptoms in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2015, 30, 14-22.	0.9	8
304	Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases. <i>European Neuropsychopharmacology</i> , 2015, 25, 2183-2184.	0.3	26
305	Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2015, 25, 1960-1967.	0.3	62
306	Comparison of continuously acquired resting state and extracted analogues from active tasks. <i>Human Brain Mapping</i> , 2015, 36, 4053-4063.	1.9	26

#	ARTICLE	IF	CITATIONS
307	Cardiovascular Adverse Reactions During Antidepressant Treatment: A Drug Surveillance Report of German-Speaking Countries Between 1993 and 2010. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu080-pyu080.	1.0	51
308	Effects of Silexan on the Serotonin-1A Receptor and Microstructure of the Human Brain: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study with Molecular and Structural Neuroimaging. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu063-pyu063.	1.0	49
309	Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv047.	1.0	83
310	P.1.i.037 Effects of norepinephrine transporter gene variants on protein binding in patients with ADHD using PET. <i>European Neuropsychopharmacology</i> , 2015, 25, S321-S322.	0.3	0
311	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. <i>International Journal of Neuroscience</i> , 2015, 125, 336-343.	0.8	7
312	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 2-7.	1.2	23
313	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 48-52.	0.9	15
314	Psychopharmakotherapie – klinisch-empirische Grundlagen. , 2015, , 1-48.		0
315	Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression. <i>Human Brain Mapping</i> , 2014, 35, 3857-3866.	1.9	50
316	Neurotransmitters and Electroconvulsive Therapy. <i>Journal of ECT</i> , 2014, 30, 116-121.	0.3	88
317	Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 685-695.	1.0	31
318	Treatment-resistant depression: a challenge for future research. <i>Acta Neuropsychiatrica</i> , 2014, 26, 131-133.	1.0	7
319	Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia. <i>International Clinical Psychopharmacology</i> , 2014, 29, 166-176.	0.9	9
320	The Norepinephrine Transporter in Attention-Deficit/Hyperactivity Disorder Investigated With Positron Emission Tomography. <i>JAMA Psychiatry</i> , 2014, 71, 1340.	6.0	44
321	Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635. <i>Psychoneuroendocrinology</i> , 2014, 45, 1-10.	1.3	23
322	Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. <i>Psychoneuroendocrinology</i> , 2014, 46, 52-63.	1.3	19
323	Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. <i>Brain Structure and Function</i> , 2014, 219, 2017-2028.	1.2	13
324	Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo. <i>Brain Structure and Function</i> , 2014, 219, 171-183.	1.2	28

#	ARTICLE	IF	CITATIONS
325	How well do randomized controlled trial data generalize to “real-world” clinical practice settings? A comparison of two generalized anxiety disorder studies. <i>European Neuropsychopharmacology</i> , 2014, 24, 125-132.	0.3	8
326	Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake. <i>NeuroImage</i> , 2014, 84, 236-244.	2.1	48
327	Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 859-869.	1.0	161
328	Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study. <i>International Journal of Bipolar Disorders</i> , 2014, 2, 13.	0.8	12
329	White Matter Microstructure in Transsexuals and Controls Investigated by Diffusion Tensor Imaging. <i>Journal of Neuroscience</i> , 2014, 34, 15466-15475.	1.7	93
330	Additive Gene-Environment Effects on Hippocampal Structure in Healthy Humans. <i>Journal of Neuroscience</i> , 2014, 34, 9917-9926.	1.7	59
331	A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. <i>European Neuropsychopharmacology</i> , 2014, 24, 1463-1474.	0.3	16
332	Imaging brain circuits in anxiety disorders. <i>Lancet Psychiatry</i> , the, 2014, 1, 251-252.	3.7	3
333	Testosterone, Neural Circuits, and Male Depression. <i>Biological Psychiatry</i> , 2014, 76, 272-273.	0.7	1
334	Brain-derived neurotrophic factor (BDNF) – Epigenetic regulation in unipolar and bipolar affective disorder. <i>Journal of Affective Disorders</i> , 2014, 168, 399-406.	2.0	74
335	Actigraphy in patients with treatment-resistant depression undergoing electroconvulsive therapy. <i>Journal of Psychiatric Research</i> , 2014, 57, 96-100.	1.5	20
336	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , 2014, 14, 463-472.	0.9	41
337	Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. <i>NeuroImage</i> , 2014, 88, 252-262.	2.1	54
338	Family history of major depression and residual symptoms in responder and non-responder depressed patients. <i>Comprehensive Psychiatry</i> , 2014, 55, 51-55.	1.5	8
339	Platelet Serotonin Transporter Function Predicts Default-Mode Network Activity. <i>PLoS ONE</i> , 2014, 9, e92543.	1.1	19
340	Exploring the Impact of BDNF Val66Met Genotype on Serotonin Transporter and Serotonin-1A Receptor Binding. <i>PLoS ONE</i> , 2014, 9, e106810.	1.1	11
341	The Impact of Genetic Polymorphisms on Neuroreceptor Imaging. , 2014, , 149-178.		0
342	Neuroimaging in Seasons and Winter Depression. , 2014, , 209-222.		0

#	ARTICLE	IF	CITATIONS
343	A gap analysis for future supply of and demand for psychiatrists in Austria. <i>Journal of Mental Health Policy and Economics</i> , 2014, 17, 9-18.	0.6	1
344	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. <i>Annals of Clinical Psychiatry</i> , 2014, 26, 243-53.	0.6	4
345	The media and intellectuals' response to medical publications: the anti-depressants' case. <i>Annals of General Psychiatry</i> , 2013, 12, 11.	1.2	16
346	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 271-278.	2.5	38
347	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 93-103.	1.8	24
348	Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. <i>Journal of Affective Disorders</i> , 2013, 151, 209-219.	2.0	64
349	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. <i>Journal of Affective Disorders</i> , 2013, 150, 649-652.	2.0	14
350	Neuropsychiatric deep brain stimulation for translational neuroimaging. <i>NeuroImage</i> , 2013, 79, 30-41.	2.1	19
351	Testosterone in the brain: Neuroimaging findings and the potential role for neuropsychopharmacology. <i>European Neuropsychopharmacology</i> , 2013, 23, 79-88.	0.3	66
352	P.2.b.044 Serotonin transporter association between dorsal raphe and ventral striatum is diminished in major depression. <i>European Neuropsychopharmacology</i> , 2013, 23, S345.	0.3	0
353	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	4.0	579
354	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm". <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 78-89.	1.2	8
355	Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. <i>Molecular Psychiatry</i> , 2013, 18, 1-1.	4.1	10
356	An orally administered lavender oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review. <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 15-22.	1.2	45
357	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2013, 23, 895-901.	0.3	28
358	RESCALE: Voxel-specific task-fMRI scaling using resting state fluctuation amplitude. <i>NeuroImage</i> , 2013, 70, 80-88.	2.1	34
359	Application of image-derived and venous input functions in major depression using [carbonyl-11C]WAY-100635. <i>Nuclear Medicine and Biology</i> , 2013, 40, 371-377.	0.3	62
360	The efficacy of agomelatine in previously-treated depressed patients. <i>European Neuropsychopharmacology</i> , 2013, 23, 814-821.	0.3	25

#	ARTICLE	IF	CITATIONS
361	Social adjustment among treatment responder patients with mood disorders. <i>Journal of Affective Disorders</i> , 2013, 150, 961-966.	2.0	2
362	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 385-391.	1.8	16
363	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 154-219.	1.3	344
364	A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. <i>CNS Spectrums</i> , 2013, 18, 163-170.	0.7	35
365	Antidepressant efficacy of agomelatine versus SSRI/SNRI. <i>International Clinical Psychopharmacology</i> , 2013, 28, 12-19.	0.9	45
366	Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 557-574.	1.0	141
367	The Impact of Adverse Life Events on Clinical Features and Interaction with Gene Variants in Mood Disorder Patients. <i>Psychopathology</i> , 2013, 46, 384-389.	1.1	10
368	Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. <i>Molecular Psychiatry</i> , 2013, 18, 93-100.	4.1	98
369	The Diagnosis and Treatment of Generalized Anxiety Disorder. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 300-9; quiz 310.	0.6	47
370	In Reply. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 610-1.	0.6	0
371	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. <i>Annals of Clinical Psychiatry</i> , 2013, 25, 97-106.	0.6	5
372	Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 739-748.	1.0	63
373	Differential modulation of the default mode network via serotonin-1A receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2619-2624.	3.3	109
374	Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression. <i>Neuropsychobiology</i> , 2012, 65, 70-75.	0.9	22
375	Actigraphic Measurements in Opioid Detoxification With Methadone or Buprenorphine. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 75-82.	0.7	17
376	Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 449-457.	1.0	32
377	Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 715-725.	1.0	7
378	Is Dopamine Neurotransmission Altered in Prodromal Schizophrenia? A Review of the Evidence. <i>Current Pharmaceutical Design</i> , 2012, 18, 1568-1579.	0.9	24

#	ARTICLE	IF	CITATIONS
379	Clinical data in early intervention. <i>International Psychogeriatrics</i> , 2012, 24, S41-S45.	0.6	7
380	Rediscovering Trazodone for the Treatment of Major Depressive Disorder. <i>CNS Drugs</i> , 2012, 26, 1033-1049.	2.7	170
381	P.4.002 Serotonin transporter ratio between raphe nuclei and projection areas predicts SSRI treatment response in major depression. <i>European Neuropsychopharmacology</i> , 2012, 22, S85.	0.3	0
382	On the application of light therapy in German-speaking countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 501-505.	1.8	17
383	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder – A European Multicenter Study. <i>European Neuropsychopharmacology</i> , 2012, 22, 259-266.	0.3	38
384	European Group for the Study of Resistant Depression (GSRD) – Where have we gone so far: Review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , 2012, 22, 453-468.	0.3	111
385	Mortality and employment after in-patient opiate detoxification. <i>European Psychiatry</i> , 2012, 27, 294-300.	0.1	3
386	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. <i>European Psychiatry</i> , 2012, 27, 114-128.	0.1	39
387	Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 413-422.	1.3	57
388	The hidden third: improving outcome in treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2012, 26, 587-602.	2.0	56
389	A highly parallelized framework for computationally intensive MR data analysis. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2012, 25, 313-320.	1.1	14
390	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. <i>Neuroscience Letters</i> , 2012, 516, 85-88.	1.0	21
391	Effects of sunshine on suicide rates. <i>Comprehensive Psychiatry</i> , 2012, 53, 535-539.	1.5	60
392	Imaging treatment effects in depression. <i>Reviews in the Neurosciences</i> , 2012, 23, 227-52.	1.4	34
393	Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 77-84.	1.2	327
394	Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl- ¹¹ C]WAY-100635 independent of arterial sampling. <i>NeuroImage</i> , 2012, 62, 199-206.	2.1	19
395	Normative database of the serotonergic system in healthy subjects using multi-tracer PET. <i>NeuroImage</i> , 2012, 63, 447-459.	2.1	126
396	Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. <i>NeuroImage</i> , 2012, 63, 874-881.	2.1	124

#	ARTICLE	IF	CITATIONS
397	Serotonin-1A receptor binding is positively associated with gray matter volume " A multimodal neuroimaging study combining PET and structural MRI. <i>NeuroImage</i> , 2012, 63, 1091-1098.	2.1	27
398	Fully exploratory network independent component analysis of the 1000 functional connectomes database. <i>Frontiers in Human Neuroscience</i> , 2012, 6, 301.	1.0	55
399	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 1-48.	1.8	113
400	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 13-22.	1.8	21
401	Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 364-375.	1.3	40
402	FC29-05 - Season, sunlight, and brain serotonin function. <i>European Psychiatry</i> , 2011, 26, 1981-1981.	0.1	1
403	Treatment Resistance in Depression. <i>European Psychiatry</i> , 2011, 26, 2022-2022.	0.1	0
404	Meta-analysis on the dissection table. <i>European Psychiatry</i> , 2011, 26, 1240-1240.	0.1	0
405	SS06-01 - Are we getting the most out of combination therapy in the short-term and long-term treatment of mania?. <i>European Psychiatry</i> , 2011, 26, 2181-2181.	0.1	0
406	FC07-06 - Differences in the modulatory role of escitalopram and citalopram revealed by effective connectivity analysis. <i>European Psychiatry</i> , 2011, 26, 1851-1851.	0.1	0
407	Database of MNI stereotactic coordinates for deep brain stimulation targets in neuropsychiatric disorders. <i>European Psychiatry</i> , 2011, 26, 1149-1149.	0.1	0
408	The viennese psychiatric intensive care unit - therapeutic modalities. <i>European Psychiatry</i> , 2011, 26, 1764-1764.	0.1	0
409	Antidepressant self-poisonings in iran. <i>European Psychiatry</i> , 2011, 26, 1268-1268.	0.1	0
410	The viennese psychiatric intensive care unit - diagnostic distribution. <i>European Psychiatry</i> , 2011, 26, 1763-1763.	0.1	1
411	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. <i>European Psychiatry</i> , 2011, 26, 1833-1833.	0.1	0
412	JS03-01 - Diagnosis and Treatment of Depression in Europe. <i>European Psychiatry</i> , 2011, 26, 2003-2003.	0.1	0
413	JS02-01 - Psychiatric intensive care. <i>European Psychiatry</i> , 2011, 26, 1999-1999.	0.1	0
414	Antipsychotics in obsessive-compulsive disorder - an auspicious approach for treatment-resistant patients?. <i>European Psychiatry</i> , 2011, 26, 1236-1236.	0.1	0

#	ARTICLE	IF	CITATIONS
415	SS05-03 - Proven antidepressant efficacy of agomelatine against the full range of symptoms. European Psychiatry, 2011, 26, 2179-2179.	0.1	0
416	Orbitofrontal hyperactivity in social anxiety disorder patients: An fmri study. European Psychiatry, 2011, 26, 179-179.	0.1	1
417	Reduced connectivity in the uncinate fiber tract between the frontal cortex and limbic subcortical areas in social phobia. European Psychiatry, 2011, 26, 182-182.	0.1	5
418	Biological alterations during remission of major depressive disorder. European Psychiatry, 2011, 26, 633-633.	0.1	0
419	Are there structural brain changes following 10 days of SSRI administration investigated by voxel-based morphometry?. European Psychiatry, 2011, 26, 913-913.	0.1	0
420	Increased functional coupling between basal ganglia and cingulate and prefrontal cortex during resting state conditions in remitted major depressive disorder. European Psychiatry, 2011, 26, 915-915.	0.1	0
421	Cortisol plasma levels are associated with serotonin - 1A receptor binding in postmenopausal women. European Psychiatry, 2011, 26, 933-933.	0.1	0
422	Efficacy of escitalopram compared to citalopram: a meta-analysis. International Journal of Neuropsychopharmacology, 2011, 14, 261-268.	1.0	35
423	Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder. NeuroImage, 2011, 56, 881-889.	2.1	353
424	Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in schizophrenic or schizoaffective patients. European Psychiatry, 2011, 26, 1415-1415.	0.1	2
425	COMT and age at onset in mood disorders: A replication and extension study. Neuroscience Letters, 2011, 498, 218-221.	1.0	32
426	Psychosocial background in incarcerated adolescents from Austria, Turkey and former Yugoslavia. Psychiatry Research, 2011, 185, 193-199.	1.7	14
427	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. Psychiatry Research, 2011, 188, 166-169.	1.7	10
428	P.1.e.027 Serotonin -1A receptor binding in the dorsal raphe nucleus is associated with hippocampal grey matter volume. European Neuropsychopharmacology, 2011, 21, S318-S319.	0.3	0
429	P.1.e.028 Resting -state functional connectivity of the raphe nuclei. European Neuropsychopharmacology, 2011, 21, S319-S320.	0.3	0
430	Intensive care in psychiatry. European Psychiatry, 2011, 26, 260-264.	0.1	12
431	Improvement of the noradrenergic symptom cluster following treatment with milnacipran. Neuropsychiatric Disease and Treatment, 2011, 7, 21.	1.0	14
432	Brain-derived neurotrophic factor gene polymorphisms. International Clinical Psychopharmacology, 2011, 26, 1-10.	0.9	67

#	ARTICLE	IF	CITATIONS
433	Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 512-516.	0.7	83
434	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. <i>Journal of Affective Disorders</i> , 2011, 128, 56-63.	2.0	45
435	Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features. <i>Journal of Affective Disorders</i> , 2011, 135, 241-250.	2.0	29
436	The genetic blueprint of major depressive disorder: Contributions of imaging genetics studies. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 474-488.	1.3	29
437	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 207-245.	1.8	40
438	Progesterone Level Predicts Serotonin-1A Receptor Binding in the Male Human Brain. <i>Neuroendocrinology</i> , 2011, 94, 84-88.	1.2	18
439	Meta-analysis: Fact or fiction? How to interpret meta-analyses. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 188-200.	1.3	42
440	Polymorphisms of the 5-HT _{2A} Receptor Gene and Clinical Response to Olanzapine in Paranoid Schizophrenia. <i>Neuropsychobiology</i> , 2011, 64, 202-210.	0.9	20
441	Bright-Light Therapy in the Treatment of Mood Disorders. <i>Neuropsychobiology</i> , 2011, 64, 152-162.	0.9	205
442	Widespread Methodological Problems Limit Validity of Meta-Analytic Results. <i>Psychotherapy and Psychosomatics</i> , 2011, 80, 246-246.	4.0	4
443	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 400-443.	1.3	168
444	A comparison of the Major Depression Inventory (MDI) and the Beck Depression Inventory (BDI) in severely depressed patients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 56-61.	1.2	34
445	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 160-187.	1.3	88
446	Psychopharmakotherapie – Klinisch-empirische Grundlagen. , 2011, , 731-766.		2
447	Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. <i>International Clinical Psychopharmacology</i> , 2010, 25, 204-213.	0.9	44
448	Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of –subsyndromal™ anxiety disorder: a randomized, double-blind, placebo controlled trial. <i>International Clinical Psychopharmacology</i> , 2010, 25, 277-287.	0.9	126
449	Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 1129-1143.	1.0	54
450	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 297-301.	0.9	18

#	ARTICLE	IF	CITATIONS
451	5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2010, 25, 228-231.	0.9	37
452	The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a caseâ€“control association study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 218-227.	0.9	51
453	Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 109-120.	1.1	218
454	The European Post-marketing Observational Sertindole Study: an investigation of the safety of antipsychotic drug treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 59-68.	1.8	29
455	The proof of efficacy in psychopharmacology: clinical studies, metaanalysis and evidence-based medicine. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2010, 260, 1-1.	1.8	1
456	Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder â€“ evidence from clinical trials. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 547-556.	0.5	51
457	SPECT Imaging. , 2010, , 1266-1270.		0
458	Milnacipran: a unique antidepressant?. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 23.	1.0	25
459	Pharmacotherapy Update: Pregabalin in the Treatment of Generalized Anxiety Disorder. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S1103.	0.4	5
460	Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 985-990.	1.3	4
461	Escitalopram Enhances the Association of Serotonin-1A Autoreceptors to Heteroreceptors in Anxiety Disorders. <i>Journal of Neuroscience</i> , 2010, 30, 14482-14489.	1.7	52
462	Interaction between serotonin 5-HT2A receptor gene and dopamine transporter (DAT1) gene polymorphisms influences personality trait of persistence in Austrian Caucasians. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 417-424.	1.3	14
463	Acute Psychotropic Effects of Oral Cannabis Extract with a Defined Content of δ^9 -Tetrahydrocannabinol (THC) in Healthy Volunteers. <i>Pharmacopsychiatry</i> , 2010, 43, 24-32.	1.7	27
464	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 81-109.	1.3	322
465	Segmentation of [11C]DASB and [carbonyl-11C]WAY-100635 PET brain images using linear discriminant analysis. <i>NeuroImage</i> , 2010, 52, S155-S156.	2.1	1
466	Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women. <i>Neuroscience Letters</i> , 2010, 476, 161-165.	1.0	15
467	Reward and the serotonergic system. <i>Neuroscience</i> , 2010, 166, 1023-1035.	1.1	220
468	Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. <i>European Neuropsychopharmacology</i> , 2010, 20, 747-765.	0.3	116

#	ARTICLE	IF	CITATIONS
469	Regional sex differences in grey matter volume are associated with sex hormones in the young adult human brain. <i>NeuroImage</i> , 2010, 49, 1205-1212.	2.1	139
470	Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study. <i>NeuroImage</i> , 2010, 49, 1161-1170.	2.1	111
471	Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 36-44.	1.3	27
472	Psycho-pharmacotherapy for anxiety and obsessive-compulsive disorder: the issue of prolonged barbiturate retention. <i>Current Medical Research and Opinion</i> , 2009, 25, 2281-2285.	0.9	3
473	Self-poisonings with tricyclic antidepressants and selective serotonin reuptake inhibitors in Tehran, Iran. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 302-312.	1.3	4
474	How to improve adherence to antipsychotic treatment: Outcomes of the IMPROVING PATIENT OUTCOMES in psychiatry (IMPACT) Berlin 2009 meeting workshop. <i>International Journal of Psychiatry in Clinical Practice</i> , 2009, 13, 245-252.	1.2	5
475	Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol – A double-blind multicenter trial. <i>Journal of Psychiatric Research</i> , 2009, 43, 702-710.	1.5	30
476	Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: A pooled analysis. <i>Journal of Psychiatric Research</i> , 2009, 43, 792-797.	1.5	18
477	Aggression is related to frontal serotonin 1A receptor distribution as revealed by PET in healthy subjects. <i>Human Brain Mapping</i> , 2009, 30, 2558-2570.	1.9	84
478	The psychiatrist confronted with a fibromyalgia patient. <i>Human Psychopharmacology</i> , 2009, 24, S25-30.	0.7	10
479	Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. <i>Molecular Psychiatry</i> , 2009, 14, 1040-1050.	4.1	87
480	Sex-specific predictors of criminal recidivism in a representative sample of incarcerated youth. <i>Comprehensive Psychiatry</i> , 2009, 50, 400-407.	1.5	54
481	The Serotonin-1A Receptor in Anxiety Disorders. <i>Biological Psychiatry</i> , 2009, 66, 627-635.	0.7	285
482	Pharmacological Properties of Psychopharmaca in Relationship to their Clinical Indications. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
483	Neuroimaging Findings and Diagnosis. <i>European Psychiatry</i> , 2009, 24, .	0.1	0
484	Anxiety Scores are Related to Amygdala Activity Induced by Facial Attractiveness and Emotional Expressions. <i>NeuroImage</i> , 2009, 47, S48.	2.1	1
485	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 85-116.	1.3	302
486	Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 117-126.	1.3	78

#	ARTICLE	IF	CITATIONS
487	Superiority of escitalopram to paroxetine in the treatment of depression. <i>European Neuropsychopharmacology</i> , 2009, 19, 229-237.	0.3	24
488	Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. <i>NeuroImage</i> , 2009, 45, 598-605.	2.1	72
489	P.1.16 Serotonin-1A receptor binding potential in dorsal raphe nuclei predicts orbitofrontal reactivity in healthy subjects. <i>European Neuropsychopharmacology</i> , 2009, 19, S15-S16.	0.3	1
490	P.2.c.002 Serotonin or noradrenalin reuptake inhibition in seasonal affective disorder: escitalopram versus reboxetine. <i>European Neuropsychopharmacology</i> , 2009, 19, S404.	0.3	1
491	Ranking antidepressants. <i>Lancet, The</i> , 2009, 373, 1760-1761.	6.3	12
492	Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. <i>International Clinical Psychopharmacology</i> , 2009, 24, 119-125.	0.9	49
493	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. <i>International Clinical Psychopharmacology</i> , 2009, 24, 250-256.	0.9	69
494	The role of pharmacogenetics in the treatment of depression and anxiety disorders. <i>International Clinical Psychopharmacology</i> , 2009, 24, 277-288.	0.9	58
495	Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. <i>International Clinical Psychopharmacology</i> , 2009, 24, 87-96.	0.9	82
496	Drug treatment of seasonal affective disorder. , 2009, , 281-296.		5
497	Social anxiety disorder: epidemiology, biology and treatment. <i>Psychiatria Danubina</i> , 2009, 21, 533-42.	0.2	11
498	The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2159-2168.	3.3	59
499	Do SSRIs or antidepressants in general increase suicidality?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 3-23.	1.8	83
500	CREB-regulated diurnal activity patterns are not indicative for depression-like symptoms in mice and men. <i>Medical Hypotheses</i> , 2008, 70, 117-121.	0.8	1
501	Humoral phototransduction: Light transportation in the blood, and possible biological effects. <i>Medical Hypotheses</i> , 2008, 71, 314-317.	0.8	11
502	S.07.04 Progesterone and estradiol plasma levels modulate serotonin-1A binding in the human brain. <i>European Neuropsychopharmacology</i> , 2008, 18, S168.	0.3	0
503	Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. <i>NeuroImage</i> , 2008, 41, 204-211.	2.1	32
504	A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. <i>European Neuropsychopharmacology</i> , 2008, 18, 122-127.	0.3	64

#	ARTICLE	IF	CITATIONS
505	Do we need another atypical antipsychotic?. European Neuropsychopharmacology, 2008, 18, S146-S152.	0.3	7
506	Continuation and long-term maintenance treatment with Hypericum extract WSÂ® 5570 after recovery from an acute episode of moderate depression â€” A double-blind, randomized, placebo controlled long-term trial. European Neuropsychopharmacology, 2008, 18, 803-813.	0.3	47
507	Neurobiological and Clinical Effects of the Antidepressant Tianeptine. CNS Drugs, 2008, 22, 15-26.	2.7	281
508	How to grade categories of evidence. World Journal of Biological Psychiatry, 2008, 9, 242-247.	1.3	22
509	Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers. Neuropsychopharmacology, 2008, 33, 1633-1641.	2.8	91
510	Enhanced Serotonin Transporter Function during Depression in Seasonal Affective Disorder. Neuropsychopharmacology, 2008, 33, 1503-1513.	2.8	85
511	Treatment of Seasonal Affective Disorder with Duloxetine: An Open-Label Study. Pharmacopsychiatry, 2008, 41, 100-105.	1.7	24
512	Everyday Problems in Treating Depression: Focus on SNRIs. CNS Spectrums, 2008, 13, 4-4.	0.7	2
513	Psychopharmakotherapie â€” Klinisch-empirische Grundlagen. , 2008, , 627-667.		1
514	Sonstige biologische Therapieverfahren (EKT, Schlafentzugsbehandlung, Lichttherapie, TMS, VNS) â€” Theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien. , 2008, , 669-690.		0
515	Nichtpharmakologische somatische Therapien. , 2008, , 727-750.		0
516	Management of acutely ill patients in the hospital setting: focus on quetiapine. International Journal of Psychiatry in Clinical Practice, 2007, 11, 61-72.	1.2	1
517	Escitalopram in Seasonal Affective Disorder: Results of an Open Trial. Pharmacopsychiatry, 2007, 40, 20-24.	1.7	28
518	Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. International Clinical Psychopharmacology, 2007, 22, 283-291.	0.9	108
519	Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology, 2007, 22, 323-329.	0.9	137
520	Binding kinetics of ¹²³ I[ADAM] in healthy controls: a selective SERT radioligand. International Journal of Neuropsychopharmacology, 2007, 10, 211.	1.0	8
521	Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 242-247.	2.5	15
522	Striatal D2 receptor occupancy in bipolar patients treated with olanzapine. European Neuropsychopharmacology, 2007, 17, 102-107.	0.3	18

#	ARTICLE	IF	CITATIONS
523	Additional support for linkage of schizophrenia and bipolar disorder to chromosome 3q29. <i>European Neuropsychopharmacology</i> , 2007, 17, 501-505.	0.3	8
524	Current issues in bipolar disorder: A critical review. <i>European Neuropsychopharmacology</i> , 2007, 17, 687-695.	0.3	56
525	Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial. <i>European Psychiatry</i> , 2007, 22, 195-202.	0.1	18
526	Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. <i>Biological Psychiatry</i> , 2007, 61, 1081-1089.	0.7	276
527	Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 661-73.	1.0	197
528	Three circadian clock genes <i>Per2</i> , <i>Arntl</i> , and <i>Npas2</i> contribute to winter depression. <i>Annals of Medicine</i> , 2007, 39, 229-238.	1.5	234
529	Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. <i>Human Psychopharmacology</i> , 2007, 22, 245-251.	0.7	8
530	Agomelatine in the treatment of seasonal affective disorder. <i>Psychopharmacology</i> , 2007, 190, 575-579.	1.5	99
531	Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [¹²³ I]ADAM SPECT study. <i>Psychopharmacology</i> , 2007, 191, 333-339.	1.5	58
532	Placebo controlled continuation treatment with <i>Hypericum</i> extract WSÂ® 5570 after recovery from a mild or moderate depressive episode. <i>Wiener Medizinische Wochenschrift</i> , 2007, 157, 362-366.	0.5	10
533	Serum lipid levels in seasonal affective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 197-202.	1.8	7
534	Season of birth in siblings of patients with seasonal affective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 378-382.	1.8	8
535	Efficacy of St. John's wort extract WSÂ® 5570 in acute treatment of mild depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 258, 59-63.	1.8	32
536	Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1062-1070.	1.1	407
537	Prinzipien der Psychopharmakotherapie. , 2007, , 1474-1481.		0
538	The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD): Report of the Korean Society of Depressive and Bipolar Disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 186-194.	1.2	14
539	Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms. <i>European Neuropsychopharmacology</i> , 2006, 16, S135-S141.	0.3	19
540	Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. <i>Schizophrenia Research</i> , 2006, 81, 139-143.	1.1	23

#	ARTICLE	IF	CITATIONS
541	Case report: Intestinal atonia as an unusual symptom of malignant catatonia responsive to electroconvulsive therapy. <i>Schizophrenia Research</i> , 2006, 84, 178-179.	1.1	6
542	Gender-specific symptoms of depression and anger attacks. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006, 3, 19-24.	0.3	32
543	Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. <i>International Clinical Psychopharmacology</i> , 2006, 21, 105-110.	0.9	74
544	In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. <i>Psychopharmacology</i> , 2006, 188, 263-272.	1.5	76
545	Superior efficacy of St John's wort extract WSÂ®5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. <i>BMC Medicine</i> , 2006, 4, 14.	2.3	77
546	Trazodone-induced cardiac arrhythmias: a report of two cases. <i>Human Psychopharmacology</i> , 2006, 21, 61-62.	0.7	17
547	Anger attacks in seasonal affective disorder. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 215.	1.0	12
548	Validation of a Simplified Definition of Anger Attacks. <i>Psychotherapy and Psychosomatics</i> , 2006, 75, 103-106.	4.0	11
549	Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 529.	1.0	5
550	Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients. <i>Neuropsychobiology</i> , 2006, 54, 152-159.	0.9	20
551	Intravenous Mirtazapine Is Safe and Effective in the Treatment of Depressed Inpatients. <i>Neuropsychobiology</i> , 2006, 53, 83-87.	0.9	10
552	Addressing the limitations of the CATIE study. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 126-127.	1.3	15
553	Treatment of seasonal affective disorder. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1039-1048.	1.4	45
554	Anxiety disorders: under-diagnosed and insufficiently treated. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 3-9.	1.2	62
555	Efficacy and Safety of Pregabalin in the Treatment of Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 771-782.	1.1	191
556	Escitalopram in the treatment of social anxiety disorder. <i>British Journal of Psychiatry</i> , 2005, 186, 222-226.	1.7	137
557	Pharmacotherapy of Seasonal Affective Disorder. <i>CNS Spectrums</i> , 2005, 10, 664-669.	0.7	15
558	Is SAD Lost to SAD?. <i>CNS Spectrums</i> , 2005, 10, 622-622.	0.7	1

#	ARTICLE	IF	CITATIONS
559	White matter hyperintensities and chronicity of depression. <i>Journal of Psychiatric Research</i> , 2005, 39, 285-293.	1.5	56
560	A Cys23→Ser23 substitution in the 5-HT receptor gene influences body weight regulation in females with seasonal affective disorder: An Austrian→Canadian collaborative study. <i>Journal of Psychiatric Research</i> , 2005, 39, 561-567.	1.5	8
561	Placebo→controlled trials in major depression are necessary and ethically justifiable. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 258-260.	1.8	19
562	Clinical efficacy in depression. , 2005, , 123-131.		0
563	Treatment challenges in the acute hospital setting. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 210-211.	1.3	2
564	Anger Attacks in Depression → Evidence for a Male Depressive Syndrome. <i>Psychotherapy and Psychosomatics</i> , 2005, 74, 303-307.	4.0	142
565	No association of clock gene T3111C polymorphism and affective disorders. <i>European Neuropsychopharmacology</i> , 2005, 15, 51-55.	0.3	43
566	Escitalopram in the Treatment of Depressed Elderly Patients. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 884-891.	0.6	91
567	Recurrent brief depression revisited. <i>International Review of Psychiatry</i> , 2005, 17, 63-70.	1.4	22
568	Psychosis as a possible side-effect of treatment with glatiramer acetate. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 487-488.	1.0	5
569	A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. <i>Current Medical Research and Opinion</i> , 2005, 21, 1139-1146.	0.9	44
570	Effect of intravenous magnesium sulphate in reducing irritability and restlessness in pure and polysubstance opiate detoxification. <i>Psychiatry Research</i> , 2005, 135, 53-63.	1.7	9
571	Actigraphy in Patients with Seasonal Affective Disorder and Healthy Control Subjects Treated with Light Therapy. <i>Biological Psychiatry</i> , 2005, 58, 331-336.	0.7	69
572	Escitalopram in the treatment of depressed elderly patients. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 884-91.	0.6	49
573	Prinzipien der Psychopharmakotherapie. , 2005, , 1311-1317.		0
574	Rezidivierende kurze depressive Episoden und Rapid Cycling. , 2005, , 503-510.		0
575	Evaluation of the Two-Way Communication Checklist as a clinical intervention. <i>British Journal of Psychiatry</i> , 2004, 184, 79-83.	1.7	57
576	Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. <i>Current Medical Research and Opinion</i> , 2004, 20, 869-878.	0.9	33

#	ARTICLE	IF	CITATIONS
577	Cost-Effectiveness of Escitalopram versus Citalopram in the Treatment of Severe Depression. <i>Annals of Pharmacotherapy</i> , 2004, 38, 954-960.	0.9	30
578	Brightening Depression. <i>Science</i> , 2004, 303, 467c-469.	6.0	64
579	Myths and Facts about Post Traumatic Stress Disorder. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 64-65.	1.3	1
580	A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 507-522.	1.0	72
581	Possible linkage of schizophrenia and bipolar affective disorder to chromosome 3q29. <i>Journal of Psychiatric Research</i> , 2004, 38, 357-364.	1.5	17
582	Gender differences in the psychopathology of depressed inpatients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 209-14.	1.8	43
583	A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. <i>Psychopharmacology</i> , 2004, 171, 390-397.	1.5	68
584	Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. <i>Depression and Anxiety</i> , 2004, 20, 44-47.	2.0	35
585	Escitalopram in the treatment of social anxiety disorder: Analysis of efficacy for different clinical subgroups and symptom dimensions. <i>Depression and Anxiety</i> , 2004, 20, 175-181.	2.0	42
586	Guided self-help versus cognitive-behavioral group therapy in the treatment of bulimia nervosa. <i>International Journal of Eating Disorders</i> , 2004, 35, 522-537.	2.1	95
587	Continuation and long-term maintenance treatment with Hypericum extract WSÂ® 5570 after successful acute treatment of mild to moderate depression â€œ rationale and study design. <i>International Journal of Methods in Psychiatric Research</i> , 2004, 13, 176-183.	1.1	7
588	Unique mechanism of action for escitalopram: does it hold the promise?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004, 8, 15-18.	1.2	7
589	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part III: Maintenance Treatment. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 120-135.	1.3	124
590	Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and in healthy controls. <i>European Neuropsychopharmacology</i> , 2004, 14, 53-58.	0.3	17
591	Bright light therapy in seasonal affective disorder â€œ does it suffice?. <i>European Neuropsychopharmacology</i> , 2004, 14, 347-351.	0.3	29
592	ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. <i>European Neuropsychopharmacology</i> , 2004, 14, 425-433.	0.3	13
593	Changing aspects of psychiatric inpatient treatment. <i>European Psychiatry</i> , 2004, 19, 483-488.	0.1	42
594	Seasonal affective disorder and the G-protein β -3-subunit C825T polymorphism. <i>Biological Psychiatry</i> , 2004, 55, 317-319.	0.7	26

#	ARTICLE	IF	CITATIONS
595	Biophotons, microtubules and CNS, is our brain a "Holographic computer"? Medical Hypotheses, 2004, 62, 169-172.	0.8	25
596	Therapy of Treatment Resistant Depression: Focus on the Management of TRD with Atypical Antipsychotics. CNS Spectrums, 2004, 9, 823-832.	0.7	17
597	Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. International Clinical Psychopharmacology, 2004, 19, 281-289.	0.9	26
598	Menstrual disturbances " a rare side-effect of bright-light therapy. International Journal of Neuropsychopharmacology, 2004, 7, 239-240.	1.0	11
599	A Pooled Analysis of 2 Placebo-Controlled 18-Month Trials of Lamotrigine and Lithium Maintenance in Bipolar I Disorder. Journal of Clinical Psychiatry, 2004, 65, 432-441.	1.1	518
600	Seasonality of Birth in Seasonal Affective Disorder. Journal of Clinical Psychiatry, 2004, 65, 1389-1393.	1.1	29
601	Demenzen. , 2004, , 250-280.		0
602	Diagnose und Behandlung der subsyndromalen SAD. , 2004, , 33-40.		0
603	Epidemiologie der saisonal abhÄngigen Depression (SAD) und ihrer subsyndromalen Form (S-SAD). , 2004, , 23-32.		0
604	Prolaktin. , 2004, , 88-108.		0
605	Bipolare affektive StÄrungen. , 2004, , 189-222.		0
606	Pharmakodynamik. , 2004, , 368-376.		0
607	International Consensus Group on Bipolar I Depression Treatment Guidelines. Journal of Clinical Psychiatry, 2004, 65, 571-9.	1.1	36
608	Placebo-controlled studies in depression: necessary, ethical and feasible. European Archives of Psychiatry and Clinical Neuroscience, 2003, 253, 22-28.	1.8	59
609	Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology, 2003, 28, 27-38.	1.3	67
610	A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Molecular Psychiatry, 2003, 8, 942-946.	4.1	103
611	Effects of tryptophan depletion and catecholamine depletion on immune parameters in patients with seasonal affective disorder in remission with light therapy. Biological Psychiatry, 2003, 53, 332-337.	0.7	17
612	Milnacipran in the treatment of bulimia nervosa: a report of 16 cases. European Neuropsychopharmacology, 2003, 13, 73-79.	0.3	24

#	ARTICLE	IF	CITATIONS
613	Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. <i>European Neuropsychopharmacology</i> , 2003, 13, 129-134.	0.3	37
614	Issues in the treatment of bipolar disorder. <i>European Neuropsychopharmacology</i> , 2003, 13, 37-42.	0.3	19
615	C825T polymorphism in the G protein β 3-Subunit gene is associated with seasonal affective disorder. <i>Biological Psychiatry</i> , 2003, 54, 682-686.	0.7	38
616	Treatment of depressive symptoms with quetiapine. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 417-423.	1.4	3
617	Circadian Clock-Related Polymorphisms in Seasonal Affective Disorder and their Relevance to Diurnal Preference. <i>Neuropsychopharmacology</i> , 2003, 28, 734-739.	2.8	307
618	Quetiapine in a delusional depressed elderly patient: no EPS and a favourable outcome. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 199-200.	1.0	1
619	Broadening the treatment indication: Is the term antipsychotic still justified?. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 144-145.	1.3	2
620	Quetiapine in the Treatment of Borderline Personality Disorder. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 42-44.	1.3	35
621	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 5-13.	1.3	148
622	Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 325-337.	1.0	272
623	Recurrent brief depressive disorder reinvestigated: a community sample of adolescents and young adults. <i>Psychological Medicine</i> , 2003, 33, 407-418.	2.7	37
624	The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. <i>Psychological Medicine</i> , 2003, 33, 785-792.	2.7	37
625	Quantification of Metabolic Differences in the Frontal Brain of Depressive Patients and Controls Obtained by 1H-MRS at 3 Tesla. <i>Investigative Radiology</i> , 2003, 38, 403-408.	3.5	136
626	Sonstige biologische Therapieverfahren (EKT, TMS, VNS, Schlafentzugsbehandlung, Lichttherapie): theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien. , 2003, , 610-629.		0
627	Relationship between Power Spectra of the Awake EEG and Psychomotor Activity Patterns Measured by Short-Term Actigraphy. <i>Neuropsychobiology</i> , 2003, 48, 176-181.	0.9	4
628	Psychiatrische Erkrankungen. , 2003, , 1265-1384.		0
629	Notfälle in der Psychiatrie. , 2003, , 429-442.		0
630	Opioid Addiction Changes Cerebral Blood Flow Symmetry. <i>Neuropsychobiology</i> , 2002, 45, 67-73.	0.9	49

#	ARTICLE	IF	CITATIONS
631	Successful Treatment of Recurrent Brief Depression with Reboxetine - A Single Case Analysis. <i>Pharmacopsychiatry</i> , 2002, 35, 75-76.	1.7	12
632	Sertindole: safety and tolerability profile. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 27-32.	1.2	10
633	Association Between Serotonin Transporter Gene Promoter Polymorphism(5HTTLPR) and Behavioral Responses to Tryptophan Depletion in Healthy Women With and Without Family History of Depression. <i>Archives of General Psychiatry</i> , 2002, 59, 613.	13.8	193
634	Maintenance treatment in depression: the role of pharmacological and psychological treatment. <i>Current Opinion in Psychiatry</i> , 2002, 15, 63-68.	3.1	12
635	Optimizing antidepressant treatment: are two actions better than one?. <i>International Clinical Psychopharmacology</i> , 2002, 17, 1.	0.9	39
636	Genome scan for susceptibility loci for schizophrenia and bipolar disorder. <i>Biological Psychiatry</i> , 2002, 52, 40-52.	0.7	95
637	Receptor and Transporter Imaging Studies in Schizophrenia, Depression, Bulimia and Tourette's Disorder—Implications for Psychopharmacology-. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 133-146.	1.3	80
638	A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. <i>European Psychiatry</i> , 2002, 17, 331s-340s.	0.1	214
639	Intravenous mirtazapine in the treatment of depressed inpatients. <i>European Neuropsychopharmacology</i> , 2002, 12, 57-60.	0.3	12
640	Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. <i>European Neuropsychopharmacology</i> , 2002, 12, 119-122.	0.3	17
641	Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder. <i>European Neuropsychopharmacology</i> , 2002, 12, 129-134.	0.3	38
642	The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. <i>European Neuropsychopharmacology</i> , 2002, 12, 461-475.	0.3	161
643	Rapid transcranial magnetic stimulation (r-TMS): A novel treatment option for seasonal affective disorder (SAD)?. <i>European Neuropsychopharmacology</i> , 2002, 12, 252.	0.3	2
644	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 171-199.	1.3	155
645	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 115-124.	1.3	161
646	Physical signs in psychiatry: a step towards evidence-based medicine. <i>International Journal of Psychiatry in Clinical Practice</i> , 2002, 6, 69-72.	1.2	2
647	Paranoid delusions and hallucinations and bright light therapy in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 1071-1072.	1.3	15
648	Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study. <i>Psychopharmacology</i> , 2002, 159, 445-446.	1.5	8

#	ARTICLE	IF	CITATIONS
649	Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. <i>Psychopharmacology</i> , 2002, 162, 42-49.	1.5	74
650	St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. <i>Psychopharmacology</i> , 2002, 164, 294-300.	1.5	86
651	Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. <i>Psychopharmacology</i> , 2002, 164, 301-308.	1.5	43
652	Intravenous antidepressant treatment: focus on citalopram. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002, 252, 105-109.	1.8	23
653	Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002, 252, 54-62.	1.8	33
654	2-COM: an instrument to facilitate patient-professional communication in routine clinical practice. <i>Acta Psychiatrica Scandinavica</i> , 2002, 106, 446-452.	2.2	23
655	Brain Serotonin 5-HT _{1A} Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635. <i>Archives of General Psychiatry</i> , 2002, 59, 514.	13.8	130
656	Partial Response and Nonresponse to Antidepressant Therapy. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 826-837.	1.1	170
657	A Longitudinal View of Triggers and Thresholds of Suicidal Behavior in Depression. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 866-873.	1.1	25
658	AminprÃkursorer. , 2002, , 627-649.		0
659	Serotonin-selektive Antidepressiva(SSRI, DSA). , 2002, , 223-363.		0
660	Atypical antipsychotics in mood disorders. <i>International Clinical Psychopharmacology</i> , 2002, 17 Suppl 3, S1-10.	0.9	2
661	Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2002, 17 Suppl 4, S19-26.	0.9	2
662	Reboxetine in seasonal affective disorder: an open trial. <i>European Neuropsychopharmacology</i> , 2001, 11, 1-5.	0.3	30
663	No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Touretteâ€™s disorder patients: a [123I]-Î²-CIT SPECT-study. <i>European Neuropsychopharmacology</i> , 2001, 11, 69-74.	0.3	48
664	Different fatal toxicity of neuroleptics identified by autopsy. <i>European Neuropsychopharmacology</i> , 2001, 11, 117-124.	0.3	28
665	Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors. <i>European Neuropsychopharmacology</i> , 2001, 11, 307-321.	0.3	53
666	Quetiapine: efficacy and tolerability in schizophrenia. <i>European Neuropsychopharmacology</i> , 2001, 11, S405-S413.	0.3	27

#	ARTICLE	IF	CITATIONS
667	[123I] β -CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. <i>Biological Psychiatry</i> , 2001, 49, 326-332.	0.7	134
668	No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. <i>Biological Psychiatry</i> , 2001, 50, 8-12.	0.7	117
669	The effects of light therapy on mini-mental state examination scores in demented patients. <i>Biological Psychiatry</i> , 2001, 50, 725-727.	0.7	82
670	Study of Family History in Seasonal Affective Disorder. <i>Neuropsychobiology</i> , 2001, 44, 65-69.	0.9	4
671	Topiramate as a mood stabilizer. <i>International Clinical Psychopharmacology</i> , 2001, 16, 295-298.	0.9	12
672	Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): health economic results of an international naturalistic study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 189-196.	0.9	27
673	Inverse Relation Between Stimulus Intensity and Seizure Duration: Implications for ECT Procedure. <i>Journal of ECT</i> , 2001, 17, 102-108.	0.3	34
674	Zotepine in the treatment of acute hospitalized schizophrenic episodes. <i>International Clinical Psychopharmacology</i> , 2001, 16, 163-168.	0.9	7
675	Fluoxetine treatment in patients with recurrent brief depression. <i>International Clinical Psychopharmacology</i> , 2001, 16, 221-226.	0.9	21
676	Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001, 16, 75-86.	0.9	147
677	A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. <i>International Clinical Psychopharmacology</i> , 2001, 16, 253-263.	0.9	54
678	Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2001, 16, 357-361.	0.9	52
679	Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. <i>Psychological Medicine</i> , 2001, 31, 1467-1473.	2.7	97
680	Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. <i>International Clinical Psychopharmacology</i> , 2001, 16, 179-187.	0.9	30
681	Monoaminergic function in the pathogenesis of seasonal affective disorder. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 409-20.	1.0	63
682	In vivo 123I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. <i>Psychopharmacology</i> , 2001, 157, 236-242.	1.5	19
683	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. <i>Acta Psychiatrica Scandinavica</i> , 2001, 104, 173-192.	2.2	367
684	Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder. <i>Journal of Affective Disorders</i> , 2001, 63, 239-242.	2.0	50

#	ARTICLE	IF	CITATIONS
685	Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET. <i>Neuropsychopharmacology</i> , 2001, 24, 522-530.	2.8	110
686	Depression and Anxiety-Separate or Continuum?. <i>World Journal of Biological Psychiatry</i> , 2001, 2, 162-163.	1.3	23
687	Inverse Relationship Between Serotonin 5-HT1A Receptor Binding and Anxiety: A [11C]WAY-100635 PET Investigation in Healthy Volunteers. <i>American Journal of Psychiatry</i> , 2001, 158, 1326-1328.	4.0	134
688	Hypericum perforatum - a Review of Clinical Studies. <i>Pharmacopsychiatry</i> , 2001, 34, 51-55.	1.7	75
689	St John's wort extract: an effective and well-tolerated antidepressant. <i>Primary Care and Community Psychiatry</i> , 2001, 7, 39-42.	0.4	6
690	Occurrence of mirtazapine-induced delirium in organic brain disorder. <i>International Clinical Psychopharmacology</i> , 2000, 15, 239-244.	0.9	17
691	Effective open-label treatment of Tourette's disorder with olanzapine. <i>International Clinical Psychopharmacology</i> , 2000, 15, 23-28.	0.9	61
692	Non-association of dopamine D4 and D2 receptor genes with personality in healthy individuals. <i>Psychiatric Genetics</i> , 2000, 10, 131-137.	0.6	54
693	Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. <i>International Clinical Psychopharmacology</i> , 2000, 15, 207-214.	0.9	23
694	Reboxetine in the treatment of bulimia nervosa: a report of seven cases. <i>International Clinical Psychopharmacology</i> , 2000, 15, 351-356.	0.9	31
695	Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. <i>Journal of Affective Disorders</i> , 2000, 60, 61-74.	2.0	118
696	The importance of treatment acceptability to patients. <i>International Journal of Psychiatry in Clinical Practice</i> , 2000, 4, 25-34.	1.2	13
697	Prevalence and Distribution of Hepatitis C Subtypes in Patients with Opioid Dependence. <i>European Addiction Research</i> , 2000, 6, 198-204.	1.3	19
698	Genome Scan for Susceptibility Loci for Schizophrenia. <i>Neuropsychobiology</i> , 2000, 42, 175-182.	0.9	68
699	Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2Î²-carbomethoxy-3Î²-(4-iodophenyl)tropane and single photon emission computed tomography. <i>Biological Psychiatry</i> , 2000, 47, 158-160.	0.7	70
700	[123I]-Î²-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. <i>Biological Psychiatry</i> , 2000, 47, 482-489.	0.7	185
701	Association study of schizophrenia spectrum disorders and dopamine D3 receptor gene: is schizoaffective disorder special?. <i>Psychiatry Research</i> , 2000, 96, 179-183.	1.7	14
702	Reboxetine: the first selective noradrenaline re-uptake inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 771-782.	0.9	202

#	ARTICLE	IF	CITATIONS
703	Review of quetiapine and its clinical applications in schizophrenia. Expert Opinion on Pharmacotherapy, 2000, 1, 783-801.	0.9	90
704	Recurrent brief depression: A frequent syndrome in clinical practice. International Journal of Psychiatry in Clinical Practice, 2000, 4, 195-199.	1.2	6
705	A time of opportunity in schizophrenia. International Journal of Psychiatry in Clinical Practice, 2000, 4, 63-65.	1.2	6
706	P02.188 1H-Magnetic resonance spectroscopy at 3.0 tesla reveals reduced n-acetyl aspartate, choline and myo-inositol levels in depression. European Psychiatry, 2000, 15, 372s-372s.	0.1	0
707	Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991 to 1997: the favourable consequences of the increasing use of SSRIs. European Neuropsychopharmacology, 2000, 10, 133-142.	0.3	52
708	Treatment of Patients With Delirium. American Journal of Psychiatry, 2000, 157, 1711-1711.	4.0	8
709	Social Functioning in Depression. Journal of Clinical Psychiatry, 2000, 61, 268-275.	1.1	464
710	Is Paranoid Schizophrenia the Most Common Subtype?. Psychopathology, 1999, 32, 98-106.	1.1	5
711	Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction, 1999, 94, 1337-1347.	1.7	144
712	Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S1-S14.	1.8	22
713	In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology, 1999, 141, 175-181.	1.5	82
714	Osteopenia in anorexia nervosa: specific mechanisms of bone loss. Journal of Psychiatric Research, 1999, 33, 349-356.	1.5	57
715	Mirtazapine in seasonal affective disorder (SAD): a preliminary report. Human Psychopharmacology, 1999, 14, 59-62.	0.7	21
716	Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S83-S89.	1.8	49
717	Atypical eating disorder in a male patient. International Journal of Psychiatry in Clinical Practice, 1999, 3, 137-139.	1.2	2
718	The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Research, 1999, 88, 75-88.	1.7	76
719	Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Research, 1999, 89, 239-246.	1.7	39
720	In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. European Neuropsychopharmacology, 1999, 9, 177-179.	0.3	47

#	ARTICLE	IF	CITATIONS
721	Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. <i>European Neuropsychopharmacology</i> , 1999, 10, 17-20.	0.3	120
722	Possible association between childhood absence epilepsy and the gene encoding GABRB3. <i>Biological Psychiatry</i> , 1999, 46, 997-1002.	0.7	57
723	Anticipation in schizophrenia. <i>Schizophrenia Research</i> , 1999, 35, 25-32.	1.1	31
724	Tryptophan depletion. <i>International Clinical Psychopharmacology</i> , 1999, 14, 313-316.	0.9	17
725	Monoamine Depletion in Non-Pharmacological Treatments for Depression. <i>Advances in Experimental Medicine and Biology</i> , 1999, 467, 29-33.	0.8	8
726	Light Treatment in Depression(SAD, s-SAD & non-SAD). , 1999, , 409-416.		5
727	Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1999, 291, 547-54.	1.3	18
728	First-episode schizophrenia: the importance of early intervention and subjective tolerability. <i>Journal of Clinical Psychiatry</i> , 1999, 60 Suppl 23, 5-9.	1.1	10
729	Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla. <i>Journal of Psychiatric Research</i> , 1998, 32, 411-420.	1.5	91
730	Social phobia: the nature of the disorder. <i>Journal of Affective Disorders</i> , 1998, 50, S3-S9.	2.0	24
731	Sertindole and dopamine D 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123 I-IBZM SPECT study. <i>Psychopharmacology</i> , 1998, 136, 367-373.	1.5	51
732	Cerebral CT findings in male opioid-dependent patients: Stereological, planimetric and linear measurements. <i>Psychiatry Research - Neuroimaging</i> , 1998, 83, 139-147.	0.9	68
733	Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients. <i>Biological Psychiatry</i> , 1998, 44, 438-447.	0.7	77
734	What Young Men Do. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998, 2, 156-156.	1.2	3
735	Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. <i>Schizophrenia Research</i> , 1998, 32, 101-106.	1.1	117
736	IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics. <i>European Psychiatry</i> , 1998, 13, 9s-14s.	0.1	6
737	IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics. <i>European Psychiatry</i> , 1998, 13, 9s-14s.	0.1	1
738	Transcultural Study of Schizophrenic Delusions. <i>Psychopathology</i> , 1998, 31, 59-68.	1.1	58

#	ARTICLE	IF	CITATIONS
739	D2-Dopamine Receptor Occupancy measured by IBZM-SPECT in Relation to Extrapyramidal Side Effects. <i>Pharmacopsychiatry</i> , 1998, 31, 159-162.	1.7	23
740	Focus on social functioning in depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 1998, 2, 241-243.	1.2	2
741	Enlarged Cerebrospinal Fluid Spaces in Opiate-Dependent Male Patients: A Stereological CT Study. <i>Neuropsychobiology</i> , 1998, 38, 80-83.	0.9	23
742	Pathological Regional Cerebral Blood Flow in Opiate-Dependent Patients during Withdrawal: A HMPAO-SPECT Study. <i>Neuropsychobiology</i> , 1998, 37, 194-199.	0.9	57
743	How much do novel antipsychotics benefit the patients?. <i>International Clinical Psychopharmacology</i> , 1998, 13, S71-S78.	0.9	11
744	Risperidone and olanzapine. <i>International Clinical Psychopharmacology</i> , 1998, 13, 253-262.	0.9	51
745	Mirtazapine in recurrent brief depression. <i>International Clinical Psychopharmacology</i> , 1998, 13, 39-40.	0.9	21
746	Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. <i>International Clinical Psychopharmacology</i> , 1998, 13, 83-86.	0.9	11
747	Occurrence of trazodone-induced delirium. <i>International Clinical Psychopharmacology</i> , 1998, 13, 225-228.	0.9	9
748	Effects of Tryptophan Depletion in Drug-Free Depressed Patients Who Responded to Total Sleep Deprivation. <i>Archives of General Psychiatry</i> , 1998, 55, 167.	13.8	58
749	Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. <i>Psychological Medicine</i> , 1998, 28, 257-264.	2.7	61
750	Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. <i>Psychological Medicine</i> , 1998, 28, 923-933.	2.7	77
751	Effects of Tryptophan Depletion vs Catecholamine Depletion in Patients With Seasonal Affective Disorder in Remission With Light Therapy. <i>Archives of General Psychiatry</i> , 1998, 55, 524.	13.8	143
752	Comments on "Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders" by Tran and Associates. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 353-354.	0.7	23
753	(Potentielle) Antipsychotika mit neuartigen Wirkmechanismen. , 1998, , 489-499.		1
754	Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder. <i>Journal of Psychiatry and Neuroscience</i> , 1998, 23, 179-80.	1.4	7
755	Depression: a long-term illness and its treatment. <i>International Clinical Psychopharmacology</i> , 1998, 13 Suppl 6, S23-6.	0.9	5
756	Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 1998, 13, 253-62.	0.9	7

#	ARTICLE	IF	CITATIONS
757	IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. <i>European Psychiatry</i> , 1998, 13 Suppl 1, 9s-14s.	0.1	1
758	Treatment of Seasonal Affective Disorder (SAD) with Hypericum Extract. <i>Pharmacopsychiatry</i> , 1997, 30, 89-93.	1.7	30
759	Editorial. <i>Pharmacopsychiatry</i> , 1997, 30, 71-71.	1.7	19
760	EPOS: Increasing our understanding of the treatment of schizophrenia; Start of a prospective referenced cohort study of sertindole in clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, 197-202.	1.2	3
761	New aspects of diagnosis and pharmacotherapy of eating disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, 21-35.	1.2	10
762	Treatment of obsessive compulsive disorder: Algorithms for pharmacotherapy. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, S17-S23.	1.2	2
763	Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. <i>American Journal of Psychiatry</i> , 1997, 154, 1153-1155.	4.0	46
764	Effects of Tryptophan Depletion on Drug-Free Patients With Seasonal Affective Disorder During a Stable Response to Bright Light Therapy. <i>Archives of General Psychiatry</i> , 1997, 54, 133.	13.8	127
765	Treatment of unipolar major depression: Algorithms for pharmacotherapy. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, S5-S7.	1.2	8
766	A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression. <i>Drug Safety</i> , 1997, 17, 251-264.	1.4	60
767	Pramipexole as adjunct to haloperidol in schizophrenia. <i>European Neuropsychopharmacology</i> , 1997, 7, 65-70.	0.3	33
768	Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. <i>European Neuropsychopharmacology</i> , 1997, 7, 115-124.	0.3	28
769	S.07.02 Therapeutic sleep deprivation: Lessons for psychopharmacology?. <i>European Neuropsychopharmacology</i> , 1997, 7, S91-S92.	0.3	0
770	P.2.069 123I IBZM spect imaging of dopamine-2 receptors in psychotic patients treated with zotepine. <i>European Neuropsychopharmacology</i> , 1997, 7, S215.	0.3	3
771	P.6.078 Personality traits in affective disorders as hints to biological disturbances. <i>European Neuropsychopharmacology</i> , 1997, 7, S288.	0.3	2
772	P.6.079 Risperidone in Gilles de la Tourette syndrome patients unresponsive to typical neuroleptics. <i>European Neuropsychopharmacology</i> , 1997, 7, S288.	0.3	0
773	P.6.083 Enhanced striatal dopamine transporter activity in drug naive and previously treated patients with gilles de la tourette syndrome (GTS): A [123I]- β^2 -CIT SPECT-study. <i>European Neuropsychopharmacology</i> , 1997, 7, S289-S290.	0.3	0
774	Sertindole and dopamine D2 receptor occupancy. <i>Biological Psychiatry</i> , 1997, 42, 161S.	0.7	4

#	ARTICLE	IF	CITATIONS
775	[123I] Î²-CIT SPECT in drug-free depressed patients with seasonal affective disorder. <i>Biological Psychiatry</i> , 1997, 42, 168S.	0.7	1
776	Diagnosis and Treatment of Subsyndromal Seasonal Affective Disorder. , 1997, 167, 11-20.		6
777	Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1997, 247, 291-296.	1.8	29
778	Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. <i>Psychopharmacology</i> , 1997, 133, 102-105.	1.5	20
779	IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. <i>Psychopharmacology</i> , 1997, 133, 323-328.	1.5	65
780	The Place of Milnacipran in the Treatment of Depression. <i>Human Psychopharmacology</i> , 1997, 12, S135-S141.	0.7	9
781	Efficacy of Antidepressants in the Treatment of Severe Depression. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 19S-28S.	0.7	37
782	Suicidal Tendencies as a Complication of Light Therapy for Seasonal Affective Disorder. <i>Journal of Clinical Psychiatry</i> , 1997, 58, 389-392.	1.1	56
783	Risperidone in the treatment of Gilles de la Tourette Syndrome. <i>European Neuropsychopharmacology</i> , 1996, 6, S4-163.	0.3	0
784	Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder. <i>Biological Psychiatry</i> , 1996, 39, 157-170.	0.7	40
785	Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. <i>Biological Psychiatry</i> , 1996, 39, 16-21.	0.7	149
786	D2 Receptor imaging (SPECT) as a tool for measuring the efficacy and side-effect profile of treatment with neuroleptics. <i>Biological Psychiatry</i> , 1996, 39, 564.	0.7	2
787	Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression A study with single photon emission computed tomography. <i>Psychiatry Research - Neuroimaging</i> , 1996, 68, 1-10.	0.9	38
788	Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. <i>Psychiatry Research - Neuroimaging</i> , 1996, 68, 23-30.	0.9	28
789	Schizophrenia and the dopamine-Î²-hydroxylase gene. <i>Psychiatric Genetics</i> , 1996, 6, 17-22.	0.6	27
790	[123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. <i>American Journal of Psychiatry</i> , 1996, 153, 183-190.	4.0	59
791	CARBOHYDRATE-DEFICIENT TRANSFERRIN AS A SCREENING MARKER FOR DRINKING IN A GENERAL HOSPITAL POPULATION. <i>Alcohol and Alcoholism</i> , 1996, 31, 249-256.	0.9	44
792	CARBOHYDRATE-DEFICIENT TRANSFERRIN AS A MARKER OF ALCOHOL INTAKE: A STUDY WITH HEALTHY SUBJECTS. <i>Alcohol and Alcoholism</i> , 1996, 31, 265-271.	0.9	73

#	ARTICLE	IF	CITATIONS
793	Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression. <i>International Clinical Psychopharmacology</i> , 1996, 11, 35-40.	0.9	85
794	Poststroke depression and fluoxetine. <i>American Journal of Psychiatry</i> , 1996, 153, 446b-447.	4.0	17
795	Low Plasma Thyroid Indices of Depressed Patients are Attenuated by Antidepressant Drugs and Influence Treatment Outcome. <i>Pharmacopsychiatry</i> , 1996, 29, 180-186.	1.7	40
796	Therapeutischer Schlafentzug und antidepressive Medikation. , 1996, , 55-67.		0
797	Schlafentzug bei Therapieresistenz auf Antidepressiva. , 1996, , 107-122.		0
798	Nebenwirkungen der Lichttherapie bei der Behandlung psychischer Erkrankungen. , 1996, , 232-236.		0
799	Kombination von Schlafentzug und Lichttherapie zur Behandlung depressiver Störungen. , 1996, , 69-80.		1
800	Rückfallverhütung nach Schlafentzug. , 1996, , 466-469.		0
801	Metabolismustheorie des therapeutischen Schlafentzugs. , 1996, , 460-465.		0
802	Risk of suicide in depression and its implication for psychopharmacological treatment. <i>International Clinical Psychopharmacology</i> , 1996, 11, 71-9.	0.9	21
803	Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. <i>Arzneimittelforschung</i> , 1996, 46, 247-50.	0.5	2
804	Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. <i>International Clinical Psychopharmacology</i> , 1995, 10, 25-35.	0.9	70
805	Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants. <i>International Clinical Psychopharmacology</i> , 1995, 9, 33-40.	0.9	130
806	Antidepressant efficacy in relation to item analysis and severity of depression. <i>International Clinical Psychopharmacology</i> , 1995, 9, 3-12.	0.9	40
807	Treatment indications for light therapy. <i>Acta Neuropsychiatrica</i> , 1995, 7, 44-46.	1.0	1
808	Trigeminal neuralgic syndrome after bright light therapy. <i>American Journal of Psychiatry</i> , 1995, 152, 1237-1237.	4.0	10
809	Transcranial magnetic stimulation (TMS) in the treatment of major depression – a pilot study. <i>Human Psychopharmacology</i> , 1995, 10, 305-310.	0.7	152
810	Involvement of mesial-temporal structures in rapid cycling mood disorders?. <i>Human Psychopharmacology</i> , 1995, 10, 475-480.	0.7	1

#	ARTICLE	IF	CITATIONS
811	Do SSRIs differ in their antidepressant efficacy. <i>Human Psychopharmacology</i> , 1995, 10, S163-S172.	0.7	16
812	?-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. <i>Journal of Neural Transmission</i> , 1995, 100, 247-256.	1.4	123
813	Diagnosis and clinical course in mood disorders and depression subtypes. <i>Depression</i> , 1995, 3, 125-128.	0.7	3
814	A Controlled Study of the Efficacy and Safety of Mianserin and Amitriptyline in Depressive Inpatients. <i>Pharmacopsychiatry</i> , 1995, 28, 249-252.	1.7	18
815	Maintenance ECT for treatment of therapy-resistant paranoid schizophrenia and Parkinson's disease. <i>Biological Psychiatry</i> , 1995, 37, 892-894.	0.7	14
816	Seasonal affective disorder in a tropical country: a case report. <i>Psychiatry Research</i> , 1995, 56, 11-15.	1.7	9
817	P-4-32 IBZM-SPECT and D2 dopamine receptor occupancy: Different profiles with atypical neuroleptics. <i>European Neuropsychopharmacology</i> , 1995, 5, 337.	0.3	4
818	Recurrent Brief Depression. <i>CNS Drugs</i> , 1995, 4, 222-229.	2.7	9
819	Algorithms for the treatment of subtypes of unipolar major depression. <i>Psychopharmacology Bulletin</i> , 1995, 31, 475-82.	0.0	12
820	Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 1995, 33, 646-52.	0.3	10
821	Hypericum in the Treatment of Seasonal Affective Disorders. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1994, 7, 29-33.	1.2	32
822	Use of light therapy in German psychiatric hospitals. <i>European Psychiatry</i> , 1994, 9, 288-292.	0.1	19
823	Cognitive Performance Test: A New Approach to Functional Assessment in Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1994, 7, 46-54.	1.2	81
824	Clinical Response to Sleep Deprivation and Auditory-Evoked Potentials - Preliminary Results. <i>Pharmacopsychiatry</i> , 1994, 27, 70-71.	1.7	9
825	Efficacy of New Generation Antidepressants: Meta-Analysis of Imipramine-Controlled Studies. <i>Pharmacopsychiatry</i> , 1994, 27, 215-223.	1.7	27
826	Evidence for a seasonal form of recurrent brief depression (RBD-seasonal). <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1994, 244, 205-210.	1.8	8
827	Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. <i>Human Psychopharmacology</i> , 1994, 9, 1-12.	0.7	38
828	Efficacy, safety, and indications for tricyclic and newer antidepressants. <i>Depression</i> , 1994, 2, 127-137.	0.7	20

#	ARTICLE	IF	CITATIONS
829	Antidepressant side effects and adverse reactions. <i>Depression</i> , 1994, 2, 138-144.	0.7	2
830	Risperidone for Tourette's syndrome. <i>Lancet, The</i> , 1994, 344, 1577-1578.	6.3	43
831	Behandlungsergebnisse mit präsynaptischen und postsynaptischen Dopamin-Agonisten bei Minussymptomatik. , 1994, , 221-239.		1
832	Application of transcranial magnetic stimulation in treatment of drug-resistant major depression-a report of two cases. <i>Human Psychopharmacology</i> , 1993, 8, 361-365.	0.7	191
833	Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. <i>European Neuropsychopharmacology</i> , 1993, 3, 13-21.	0.3	67
834	Is severe depression a different illness? The pharmacological evidence. <i>European Neuropsychopharmacology</i> , 1993, 3, 215-217.	0.3	4
835	Hormonal markers of response to antidepressive treatment. <i>European Neuropsychopharmacology</i> , 1993, 3, 321-322.	0.3	0
836	Nicht-trizyklische Antidepressiva. , 1993, , 105-268.		2
837	Objektivierung der quantitativen Lichtexposition während Lichttherapie durch kontinuierliche photometrische Aufzeichnung. , 1993, , 268-271.		0
838	Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs). , 1993, , 163-182.		1
839	Quantitatives EEG und Ansprechen auf therapeutischen Schlafentzug bei depressiven Patienten. , 1993, , 217-220.		1
840	Tissue-specific regulation of vasoactive intestinal peptide messenger ribonucleic acid levels by estrogen in the rat.. <i>Endocrinology</i> , 1992, 130, 1796-1801.	1.4	19
841	Comparative Efficacy of Antidepressants. <i>Drugs</i> , 1992, 43, 11-23.	4.9	111
842	Early clinical results with the neuroleptic roxindole (EMD 49 980) in the treatment of schizophrenia – an open study. <i>European Neuropsychopharmacology</i> , 1992, 2, 91-95.	0.3	11
843	Thyroid hormones, body temperature, and antidepressant treatment. <i>Biological Psychiatry</i> , 1992, 31, 859-862.	0.7	25
844	Recurrent brief depression and its relationship to seasonal affective disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1992, 242, 20-26.	1.8	25
845	Therapeutischer Schlafentzug und Resistenz auf Antidepressiva – Neuroendokrinologische und klinische Befunde. , 1992, , 446-448.		0
846	Reduzierte Amplitude zirkadianer Hormonprofile bei Patienten mit saisonal abhängiger Depression (SAD). , 1992, , 356-359.		1

#	ARTICLE	IF	CITATIONS
847	Contrasts between symptoms of summer depression and winter depression. <i>Journal of Affective Disorders</i> , 1991, 23, 173-183.	2.0	62
848	Therapeutic sleep deprivation and antidepressant medication in patients with major depression. <i>European Neuropsychopharmacology</i> , 1991, 1, 107-111.	0.3	15
849	Immunological correlates of seasonal fluctuations in mood and behavior and their relationship to phototherapy. <i>Psychiatry Research</i> , 1991, 36, 253-264.	1.7	18
850	Evaluation of seasonality in six clinical populations and two normal populations. <i>Journal of Psychiatric Research</i> , 1991, 25, 75-87.	1.5	136
851	Abnormal Pituitary-Adrenal Responses to Corticotropin-Releasing Hormone in Patients with Seasonal Affective Disorder: Clinical and Pathophysiological Implications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 1382-1387.	1.8	136
852	Jahreszeit und Befindlichkeit in der Allgemeinbevölkerung. <i>Monographien Aus Dem Gesamtgebiete Der Psychiatrie</i> , 1991, , .	0.1	11
853	Multiple Hormone Responses to Stimulation with dl-Fenfluramine in Patients with Major Depression before and after Antidepressive Treatment. <i>Pharmacopsychiatry</i> , 1990, 23, 76-84.	1.7	30
854	Response to Total Sleep Deprivation Before and During Treatment with Fluvoxamine or Maprotiline in Patients with Major Depression - Results of a Double-Blind Study. <i>Pharmacopsychiatry</i> , 1990, 23, 135-142.	1.7	45
855	Effects of light treatment on core body temperature in seasonal affective disorder. <i>Biological Psychiatry</i> , 1990, 27, 39-50.	0.7	69
856	The effects of phototherapy in the general population. <i>Journal of Affective Disorders</i> , 1990, 18, 211-219.	2.0	57
857	Seasonality in major depressed inpatients. <i>Journal of Affective Disorders</i> , 1990, 19, 243-248.	2.0	40
858	Schlafentzugstherapie "eine Chance bei Antidepressiva-Nonresponse? , 1990, , 149-166.		12
859	Phototherapy in Individuals With and Without Subsyndromal Seasonal Affective Disorder. <i>Archives of General Psychiatry</i> , 1989, 46, 837.	13.8	220
860	Epidemiological Findings of Seasonal Changes in Mood and Behavior. <i>Archives of General Psychiatry</i> , 1989, 46, 823.	13.8	577
861	Seasonal changes in mood and behavior: A cluster analytic approach. <i>Psychiatry Research</i> , 1989, 28, 227-239.	1.7	35
862	Judgement of the hypothalamic-pituitary-adrenocortical function in psychiatric patients by betamethasone-induced cortisol suppressibility. <i>Journal of Neural Transmission</i> , 1988, 74, 161-174.	1.4	1
863	Auditory evoked potentials and total sleep deprivation in depressed patients. <i>Psychiatry Research</i> , 1988, 25, 91-100.	1.7	20
864	Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression. <i>Biological Psychiatry</i> , 1988, 24, 631-641.	0.7	66

#	ARTICLE	IF	CITATIONS
865	Phototherapy in Subsyndromal Seasonal Affective Disorder (S-SAD) and "Diagnosed" Controls. <i>Pharmacopsychiatry</i> , 1988, 21, 428-429.	1.7	26
866	Neurobiology of Seasonal Affective Disorder and Phototherapy. <i>Journal of Biological Rhythms</i> , 1988, 3, 135-154.	1.4	82
867	Serotonergically induced hormonal responses and the antidepressant effect of total sleep deprivation in patients with major depression. <i>Psychopharmacology Bulletin</i> , 1988, 24, 450-3.	0.0	12
868	Personality as a dimension of summer and winter depression. <i>Psychopharmacology Bulletin</i> , 1988, 24, 476-83.	0.0	10
869	Dexamethasone suppression test in a pluri-diagnostic approach: its relationship to psychopathological and clinical variables. <i>Acta Psychiatrica Scandinavica</i> , 1983, 68, 31-37.	2.2	55
870	Dexamethasone Suppression Test Combined with Total Sleep Deprivation in Depressed Patients. <i>Psychopathology</i> , 1983, 16, 17-25.	1.1	2
871	Low platelet MAO activity and schizophrenia: sex differences. <i>Acta Psychiatrica Scandinavica</i> , 1981, 64, 167-174.	2.2	21
872	Trazodone and Amitriptyline in Treatment of Depressed Inpatients. <i>Pharmacopsychiatry</i> , 1981, 14, 167-171.	1.7	23
873	The Anticholinergic Biperiden in Depressive Disorders. <i>Pharmacopsychiatry</i> , 1981, 14, 195-198.	1.7	64
874	HL-A-antigens, schizophrenia and brain atrophy. <i>British Journal of Psychiatry</i> , 1980, 137, 398-9.	1.7	0
875	Editorial 2. <i>International Journal of Psychiatry in Clinical Practice</i> , 0, , 1-2.	1.2	0
876	The Impact of Theta-Burst Stimulation on Cortical GABA and Glutamate in Treatment-Resistant Depression: A Surface-Based MRSI Analysis Approach. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	3